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INTRODUCTION: Resistance to cell death is one of the well-known hallmarks of cancer. 
Metastatic melanoma is an aggressive disease whose treatment has significantly improved 
thanks to the recent development of either target-specific or immune-modulating agents. 
Since the FDA approval of the BRAFV600E inhibitor Vemurafenib in 2011, several other 
inhibitors, targeting relevant oncogenic signalling pathways (i.e. the MEK/ERK or the 
PI3K/Akt/mTOR pathways) have been used to treat melanoma patients. However intrinsic or 
acquired resistance limits the efficacy of these compounds, with relapses in most of the 
patients within 6 months. Therefore, there is an immediate necessity for new therapeutic 
strategies to face this issue, and one option could be represented by combinatorial 
treatments associating different anti-tumor agents able to target not only tumor cells but also 
to counteract pro-tumoral mechanisms in melanoma microenvironment. 
 
HYPOTHESIS: Our goal was to obtain pre-clinical evidence  for the efficacy of an anti-tumor 
approach based on the combination of MEK, PI3K inhibitors and TRAIL; building upon the 
hypothesis that these agents should:  
1) be able to overcome melanoma intrinsic resistance to programmed cell death by the 
concomitant targeting of both the extrinsic (mainly through TRAIL activity) and the intrinsic 
(mainly due to the activity of MEK and PI3K pathway inhibitors)  apoptosis pathways; 
2) be able to promote an anti-angiogenic effect combining the well-known vascular disrupting 
activity of TRAIL and the effects of inhibition of pro-angiogenic pathways in tumor and in 
tumor-associated vasculature due to targeting of ERK and AKT cascades. 
 
METHODS: A large panel of patient-derived melanoma cell lines was used to test the in vitro 
efficacy of the association between AZD6244/Selumetinib (a MEK1/2 inhibitor), the dual 
PI3K/mTOR inhibitor BEZ235, and soluble TRAIL. Chou-Talalay drug interaction analysis 
was used to determine Combination Indexes and Fraction Affected values for all the possible 
combinations of anti-tumor agents. Whole-genome gene expression profiling, flow cytometry 
experiments, western blot analysis, proteomic arrays and ELISAs were used to clarify the 
mechanism behind the synergy shown for the AZD6244+TRAIL and 
AZD6244+BEZ235+TRAIL associations. Moreover, xenografts in SCID mice were used to 
confirm the in vivo efficacy and mechanism of action of the combination between the MEK 
inhibitor and TRAIL, using tumor growth rates and immunohistochemistry on tumor nodules 
to evaluate effects of the association. Human Umbilical Vein Endothelial Cells (HUVEC) 
were chosen to model the endothelial-melanoma cell interaction in order to analyze its 
effects on response to the combinatorial treatment, both in terms of apoptosis induction and 
endothelial differentiation/activation status. 
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RESULTS: While half of the melanoma cell lines we tested were resistant to the death 
receptor ligand TRAIL, several were susceptible either to AZD6244 or to BEZ235, 
evidencing independent susceptibility profiles to these drugs and setting the rationale for 
their association. The combination of the MEK inhibitor, with or without the PI3K/mTOR 
inhibitor, and TRAIL achieved synergistic anti-tumor activity in 20/21 melanoma cell lines 
tested, including tumors resistant to either one of the agents. 
Mechanistically, an increment in induction of caspase-dependent cell death and of 
mitochondrial depolarization was evidenced for the association, and a significant modulation 
of key regulators of extrinsic and intrinsic apoptosis pathways including c-FLIP, BIM, BAX, 
clusterin, Mcl-1 and several IAP family members was confirmed. Moreover, silencing 
experiments defined Apollon downmodulation as a central event for the promotion of the 
melanoma apoptotic response to our combinatorial treatments.  
SCID mice bearing melanoma xenografts were treated with the MEK inhibitor and TRAIL, 
alone or in combination, obtaining a more significant tumor growth inhibition by the 
combinatorial treatment, with no detectable adverse events on mice body weight and tissue 
histology. TUNEL staining on tissues sections indicated also in vivo an increased promotion 
of tumor apoptosis, which was associated with suppression of several pro-angiogenic 
molecules like HIF1, VEGF, IL-8 and TGF1as well as a marked reduction in CD31 
positive cells. 
Furthermore, initial results on HUVECs pointed at a possible effect of the interaction 
between endothelial and melanoma cells, affecting responsiveness of HUVECs to 
combinatorial treatments, as documented by increased endothelial cell apoptosis, in 
response to MEK inhibitor and TRAIL treatment, after co-culture with melanoma cells.  The 
modulatory effect of melanoma on endothelial cells was evidenced not only by “activation” 
markers (upregulation of ICAM-1/CD54) but also the “differentiation” status of endothelial 
cells, indicated by increased alpha-SMA levels, reduction in the expression of vascular 
cadherin CD144 and downmodulation of the endothelial marker CD31. 
 
CONCLUSIONS: Results of this work suggest that concomitant targeting of melanoma 
oncogenic signalling pathways and the TRAIL receptor cascade can not only overcome in 
vitro tumor resistance to different anti-tumor agents, but can also have in vivo effects on 
tumor microenvironment, promoting pro-apoptotic effects and inhibition of tumor 
angiogenesis. Moreover, this could be associated to a modulation of endothelium 
responsiveness to anti tumor agents by direct interaction with melanoma cells. 
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1.1 METASTATIC MELANOMA: AN AGGRESSIVE DISEASE WITH A 
POOR PROGNOSIS 
 
1.1.1 Incidence, origin and classification  
 
Melanoma is one of the most aggressive human cancers, representing less than 4% of all 
skin neoplasms, yet being responsible for more than 75% of deaths related to cutaneous 




Cutaneous melanomas origin from aberrant transformations occurring in melanocytes, the 
melanin-producing cells of the body, responsible for skin pigmentation and sun protection.
3
 
Exposure to UV light increases skin pigmentation through the activity of the -melanocyte 
stimulating hormone (-MSH) secreted by keratinocytes after a p53-dependent induction of 
proopiomelanocortin (POMC) and its post-translational cleavage.
4
  Melanocytes express the 
melanocortin 1 receptor (MC1R) 
5
 that, upon binding to -MSH, promotes pigment synthesis 
and melanin production through the activation of the microphthalmia-associated transcription 
factor (MITF), which is considered the “master regulator” of melanocyte biology and whose 
levels determine the activation of different sets of target genes. 3 
 
 
Figure 1.1: UVR response in melanocytes. UVR-induced DNA damage induces p53 activation in 
keratinocytes and consequant up-regulation of proopiomelanocortin (POMC). -endorphin and -MSH 
are produced by post-translational cleavage of POMC and the secreted -MSH is the ligand for MC1R  
on melanocytes. Its activation results in melanin synthesis and  transfer to keratinocytes.  
 
Melanomas can occur de novo or progress from pre-existing benign nevi through different 
and subsequent histological phases. 
6
 
The Clark model was the first to describe morphological changes that characterize 
melanomagenesis and progression from normal skin to malignant melanoma. 
7
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The first phenotypic change is the onset of a benign nevus: here the control of cell growth is 
disrupted but aberrant proliferation is still limited. At molecular level we can find abnormal 
activation of the mitogen-activated protein-kinases (MAPK) pathway, possibly due to somatic 
mutation in N-RAS or BRAF, key components of the MAPK cascade. The next event gives 
rise to a dysplastic nevus, associated with abnormalities in mechanisms that control cell 
cycle progression after DNA repair (i.e. deletion in cyclin-dependent kinase inhibitor 2A 
(CDKN2A)) and susceptibility to cell death (i.e. deletions of the phosphatase and tensin 
homologue (PTEN)).  Further progression generates in situ melanoma, characterized by a 
radial growth phase (RGP) were melanoma cells spread in the upper epidermis; this step 
can be associated with decreased activity of MITF and consequent decrease in 
differentiation and expression of melanoma markers. Malignant melanoma is marked by 
more rapid vertical growth phase (VGP) were neoplastic cells invades the dermis and 
deeper structures and can metastasize and spread throughout the body. 
7
 




Figure 1.2: Melanomagenesis. A) Skin composition under physiological conditions; B) Nevi are 
characterized by atypical growth of melanocytes and can become dysplastic; C) Radial-growth-phase 
(RGP) melanoma is the first malignant stage; D) Vertical-growth-phase (VGP) melanoma, at this stage 
melanoma cells acquire metastatic potential and can infiltrate the vascular and lymphatic systems. 
 
A more recent study by Hunter Shain et al. 
8
 has proposed a model for the genetic evolution 
of melanoma. As shown in Figure 1.3, they have reported that all benign lesions harbor 
BRAF V600E pathogenic alteration, therefore demonstrating that this mutations is sufficient 
to form a nevus. The progression towards a malignant lesion is then initiated by other 
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mutations that affect the MAPK cascade (NRAS or other BRAF mutations), followed by 
TERT mutations, characteristics that have been proposed to define “intermediate lesions”. 
The presence of TERT mutations at these early stages suggests that precursors cells 
(naevus cells) that exhaust their replicative potential proceed toward a replicative 
senescence 
9
, while other precursors can bypass this mechanism, keep on dividing, and 




Figure 1.3: Proposed model for melanoma progression and corresponding genetic alterations.  
 
Melanomas can be classified based on site of origin, tumor thickness and histologic subtype. 
More than 90% of all melanomas are from cutaneous origin, but other primary sites of onset 
include mucosal, uveal and leptomeningeal.  
Classification of cutaneous melanomas defines four major subtypes, with different patterns 
of growth and anatomic locations: superficial spreading (SSM), lentigo maligna (LM), acral 






Figure 4: Different type of cutaneous melanoma. A) Superficial spreading melanoma. B) Nodular 
melanoma. C) Lentigo maligna melanoma. D) Acral lentiginous melanoma  
 
While superficial spreading melanoma can be found in any part of the skin but is most 
frequent on sites with acute-intermittent sun exposure, NM (nodular melanoma) is the 
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second most common subtype and is particularly localized on the trunk, head and neck. 
Different types have distinct biological and clinical behaviors: for example lentigo maligna 
are indolent tumors that develop over decades on chronically sun-exposed area such as the 
face, while, on the other hand, acral lentigenous melanoma is usually found on palms, soles 





Table 1.1: Classification of melanoma.  
 
The TNM Classification of Malignant Tumours (TNM) is a globally used system that 
describes the stage of a solid tumor based on three main parameters
12
: 
 T describes the size of the primary tumor and whether it has invaded other tissues, 
 N describes involvement of regional lymph nodes, 
 M describes presence/absence of distant metastasis. 
 
Guidelines of the American Joint Committee on Cancer (AJCC) and the Union for 
International Cancer Control (UICC) determine the classification of melanomas on the bases 
of tumor thickness, mitotic rate and ulceration, histological features that indicate prognosis 
and define staging, paralleled by number and extent of metastases (summarized in table 
2).
13
 Classification should be done after the initial excisional biopsy of the lesion, followed by 
a sentinel lymph node biopsy if needed. 
Of note, as tumor thickness increases there is a significant decline in survival rates: for 
patients with T1 melanomas (thickness <1 mm) 10-year survival rates is 92%; 80% for 
patients with T2 melanomas (thickness 1.01-2.00 mm); 63% for T3 staged patients 
(thickness 2.01-4.00 mm) and for patients with melanomas more than 4.00 mm thick (T4) the 
survival rate dropped to less than 50%. 
13
 Moreover, survival of patients with an ulcerated 
melanoma is significantly lower than for patients with equivalent T stage but with no 
ulceration. Furthermore, tumor mitotic rate, defined as the threshold of 1/mm
2
, is a powerful 
and, most important, independent prognostic factor. 
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Table 1.2: Guidelines for primary tumor and regional lymph node staging.  
 
Clinical staging identifies five classes, from 0 to IV, with increasing degrees of invasiveness 
and worsening prognosis. In the absence of known distant metastasis, the extent of regional 
lymph node involvement and number of lymph nodes invaded by the disease become other 
prognostic indicators. (Table 2) 
Melanoma at its early stages is generally cured by excisional surgery with good results, 






Figure 1.5: Survival rates for the different staging groups of melanoma patients. 
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1.1.2 Melanoma risk factors 
 
Melanoma is a multi- factorial disease and its development depends on both environmental 
and genetic contributions.  
 
UV exposure 
Several epidemiological studies have firmly established that the major melanoma risk factor 
is ultraviolet (UV) radiation, with the highest risk associated to an intermittent and intense 
UVR exposure, along with sunburns during childhood. 
15,16
 
The effects on the skin of ultraviolet radiation are diverse and include, besides to genetic 
changes that account for the high mutation rate of melanoma, also an induction of reactive 




Both UVA and UVB can induce DNA damage, UVB through direct mutagenesis at 
dipyrimidine sites that can result in C>T mutations, while UVA indirectly inducing the 
formation of reactive oxygen species (ROS) and subsequently G>T transversion mutations 
due to oxidative damage.
3
  In 2012 a whole-exome sequences study defined that about 50% 
of melanoma driver mutations can be attributed to C>T and G>T transitions (UV-signature), 
most of which occurring in tumor suppressor genes such as CDKN2A, PTEN and TP53.
17
 
Recent studies involving mouse models have demonstrated plural links between UV 
exposures and melanomagenesis; specifically, Zaidi et al. showed that UVB can induce 
melanocyte activation through an interferon-dependentinflammatory response.
18
 
Moreover, Viros et al. demonstrated that in mice, UVR can accelerate BRAF-driven 
melanomagenesis through alterations in TP53 gene.
19
 Furthermore, UV exposure has been 
shown to promote melanoma metastatic progression enhancing perivascular invasion of 






Heritable phenotypic risk factors include phototype (a fair skin, blue or green eyes, blonde or 
red hair are associated with an incremented incidence of melanomas), sun sensitivity, an 
inability to tan
18-20
. A high number of melanocytic naevi, or the presence of clinically atypical 
naevi are also connected to an augmented risk of melanoma onset.  
Moreover, somatic mutations randomly acquired by melanocytes and accumulation of 
genomic changes can influence melanoma onset: candidate-gene studies and genome-wide 
association studies (GWAS) for melanoma and these melanoma-associated phenotypes 
have identified sever variants associated with melanoma risk in the general population.
21-24
   
Nevertheless, the presence of germ line variants can be predisposing and family history is 
among the strongest risk factors.  
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Indeed, about 10% of melanoma cases occur in families where patients report close 
relatives affected, and mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A) are 
present in 20-40% of  familial melanoma, being therefore the most common. 
25
 The CDKN2A 
gene encodes for two transcripts generated by two different splicing variants: p16 inhibitor of 
cyclin-dependent kinase 4 (p16INK4A) and the alternate reading frame (p14ARF). The latest 
controls positively p53 activity, therefore a loss of function impacts on proliferation control of 
DNA damaged cells. p16INK4A, instead, regulates the phosphorylation status of the 
oncosuppressor retinoblastoma protein (RB) through the inhibition of CDK4 and CDK6. 
26
 
Other high penetrance melanoma predisposition genes are CDK4, whose mutations impact 
on the same pathway affected by CDKN2A mutations 
27
, inactivating alterations in BRACA1-
associated protein-1 (BAP1) 
28
 or substitutions in MITF gene sequence and alterations in the 





1.1.3 Molecular classification of sporadic melanoma 
 
Interestingly, a recent paper published by the “cancer genome atlas network” has defined a 
framework for the genomic classification of cutaneous melanomas, through an integrated 
analysis of DNA, RNA and proteins from a large collection of 333 samples from melanoma 
patients. 
30
 Referring to the most mutated genes, they identified 4 different melanoma 
subtypes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type), linking the 
genomic setting to possible response to targeted therapies, therefore proposing a guide for 








Table 1.3: Mutational subtypes and clinical implications.  
 
 
Table 3 summarizes the four identified subtypes and the predicted genetic alterations are 
indicated; in each one of the genomic classes a subset of melanomas expresses significant 
immune infiltration markers.  
The different extent of immune infiltration, which is independent from the specific subtype, 
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1.2 ONCOGENIC SIGNALLING PATHWAYS IN MELANOMA 
 
Most if not all genetic alterations present in melanoma cells have as a consequence the 
constitutive activation of either the MAPK pathway or the PI3K/AKT/mTOR pathway. To 
better understand the molecules involved, I will briefly describe the main components of the 
two cascades. 
 
1.2.1 The Mitogen Activated Protein Kinase (MAPK) cascade 
 
Mitogen-activated protein kinases (MAPK) are serine, threonine, and tyrosine 
specific protein kinases, involved in responses to multiple stimuli and that regulate a wide 




Mammalian cells possess four main MAPKs cascades, activated by distinct signals. Each 
cascade is a hierarchical pathway built on three protein kinases that act one after the other 
using phosphorylation to activate their substrates: the upstream elements are the MAPK 
kinase kinase (MAPKKK), then the intermediate MAPK kinase (MAPKK) and then the 
“effector” kinases, the MAPK. 
32
 (Figure 7) 
The four different terminal kinases are the ERK1/2, the c-Jun amino terminal kinases 
(JNK1/2/3), p38 kinases and ERK5/BMK1. Each cascade can be activated by different 
stimuli, both internal, such as DNA damage or metabolic stress, and extrinsic like cell-matrix 
interactions or growth factors response. The most known and studied is the “canonical” 
pathway, the RAS-RAF-MEK-ERK. 
33
 
Normally, when a ligand (i.e. the Epidermal Growth Factor (EGF)) binds to its receptor on 
the plasma membrane RAS GTPases activity is stimulated. Active RAS interacts with the 
MAPKKK of the RAF family inducing membrane translocation, dimerization and activation. 
RAF kinases then phosphorylate in serine-threonine residues the MEK kinases, which 
subsequently activate ERK. 
34
 
All components of this pathway are present in different isoforms: two subtypes of ERK 
(ERK1 and ERK2), two subtypes of MEK (MEK1 and MEK2), three subtypes of RAF (ARAF, 
BRAF and CRAF) and three subtypes of RAS (HRAS, NRAS and KRAS) have been 
described and characterize, increasing the complexity of this pathway.
35
 
Active ERK has substrates both in the cytoplasm, where it can phosphorylate cytoskeletal 
proteins affecting cell movement, or many other substrates such as ribosomal S6 kinases 
36
(RSKs); or ERK can translocate into the nucleus activating several transcription factors.
37
 
In immune cells it induces the expression of tumor necrosis factor alpha (TNF) and 
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Figure 1.6: The mammalian MAPK cascade.  
 
Several studies have demonstrated that the ERK1/2 MAPK pathway is a key controller of 
cell proliferation and survival. 
39
 Both ERK1 and ERK2 are activated in response to 
mitogenic stimuli and multiple line of evidence have reported the correlation between 
mitogenic response to growth factors and the ability to activate ERK1/2 
40
 as well as the fact 
that silencing these proteins is able to inhibit proliferation of different type of cells.
41
 Findings 
confirmed by the evidence that small molecules inhibitors targeting MEK are able to inhibit 
cell proliferation 
42
 and, conversely, the induced expression of MEK is sufficient to stimulate 
cell replicative potential. 
43
 Furthermore, activation of signalling mediated by ERK1/2 has 
been shown to induce cell cycle progression 
44
, to activate cell cycle regulators such as 
cyclin D1 
45
 and c-Myc 
46
 and to down regulate several proteins such as p21. Moreover, the 
activation of MAPK/ERK signalling induces biosynthesis of nucleotide and proteins. 
47
 
Interestingly, several studies have shown that ERK1/2 activity promotes cell proliferation and 
survival acting on the expression of both pro-survival molecules such as Bcl-2 and Mcl-1 as 
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1.2.2 The PI3K-AKT-mTOR signalling pathway 
 
The phosphoinositide-3 kinase (PI3K)/ v-Akt murine thymoma viral oncogene (AKT) 
mammalian target of rapamycin (mTOR) signalling pathway is among the most important 
pathways that regulate cell proliferation and survival as well as transcription and motility. 
49
 
PI3K cascade is usually activated by receptor tyrosin kinases (RTKs) engagement, but it can 
also respond to several type of cytokines.
50
  
Class I PI3 kinases are present in different isoforms and  and formed by heterodimers 
of a regulatory subunit (p85/p55/p50) and a catalytic subunit (p100), whose activation 
induces phosphorylation of the phosphatidylinositol-4,5-biphosphate (PIP2), generating 
phosphatidylinositol-3,4,5-triphosphate (PIP3). 
51
 The latest recruits several adaptor and 
effector  proteins to cellular membrane and leads to the activation, through the 
phosphorylating activity of the phosphoinositide-dependent kinase 1 (PDK1), of protein 
kinase B (AKT), the main node in PI3K pathway. 
52
 
AKT is a serine/threonine-specific protein kinase involved in multiple cellular processes; 
once activated it is able to phosphorylate a high number of target proteins, regulating their 
activity either positively or negatively. 
53
  
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the key 
molecules that negatively regulate the PI3K pathway through a dephosphorylating activity on 




Akt activity is implicated in cell cycle progression and protein synthesis through the 
regulation of several proteins such as the glycogen synthase kinase-3 (GSK-3), the 
forkhead transcription factors, cyclin kinase inhibitors p21 and p27 and mTOR. 
55
  Moreover, 
Akt contributes to the stabilization of cyclin D1 and c-Myc through the inhibition of GSK3
56
 
Also, Akt can promote the degradation of the oncosuppressor p53 by phosphorylating and 
thereby activating its negative regulator Mdm2. 
57
 
Furthermore, several studies have demonstrated that PI3K/Akt signalling is anti-apoptotic 
through different activities on multiple proteins. For example, Akt can inhibit caspase-9 
activity, a crucial initiator of the apoptotic cascade 
58
; similarly, PKB/Akt phosphorylates BAD 
and thus releases the anti-apoptotic members of the Bcl-2 family. 
59
 Moreover, Akt can 
activate and phosphorylate I-kB kinase, finally leading to the activation of the transcription 
factor NF-kB, which has among its targets Bcl-2 and Bcl-XL. 
60
  
Activation of mTOR is able to control cell growth through the activation of p70S6K and 
inhibition of 4E-BP1, two molecules that control protein translation. 
61
 
Besides melanoma, the activation of PI3K/Akt signalling pathway has been found in many 
other different type of human cancer; among them breast cancers, tumors of the lung, ovary, 
thyroid, pancreas and stomach, as well as glioblastoma and several hematological 




 Moreover, similar studies have highlighted correlations between Akt 
activation and advanced stage, histological grade or poor prognosis. 
62
 
Specifically, Akt activation in human cancer can be due to several different mechanisms; 





) as well as alterations in PTEN (usually loss of function via gene 
mutation, deletion or promoter methylation. 
65
 
Of note, constitutive or residual PI3K pathway activation has been found in cells that have 
developed resistance to conventional chemotherapy and radiation, as well as resistance to 




Importantly, MAPK and PI3K pathways often cross-interact, usually through reciprocal 
regulation with positive or negative feedbacks, and the activation of either one of the two 
cascades can converge in the activation of common downstream target proteins (i.e several 
transcription factors or protein kinases). For instance, hyper-activated RAS can induce, 
aside from MAPK pathway induction, also the PI3K cascade 
67
; similarly, PI3K pathway 
inhibition can induce a rebound effect and can induce phosphorylation of ERK or of other 
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1.3  COMMON GENETIC ALTERATIONS IN MELANOMA 
 
The development of human cancers is a multi-step process during which normal cells 
acquire, through accumulation of genetic and epigenetic alterations, several “malignant” 
characteristics (or “hallmarks”) that render them able to evade proliferation control. 
69
 
The hallmarks of cancer first described by Hanahan and Weinberg in 2000, 
69
 comprise self-
sufficiency from growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis.  
Melanoma cells acquire these characteristics mainly through alterations in signalling 
molecules, cell cycle and proliferation regulators, and transcription factors/ epigenetic 
regulators; all of which have as a consequence an hyperactivation of either the MAPK or the 
PI3K cascades.
70
 (Figure 7) 
 
 
Figure 1.7: Signalling pathways in melanoma. MAPK signalling promotes cell growth and survival 
and is constitutively active in most melanomas. RAS family members are activated by RTKs and signal 
through effector proteins, including RAF kinases, PI3K, and Ral-GEFs. Oncogenic BRAF and NRAS 
are found in 40 to 60% and 10 to 30% of melanomas, respectively. c-KIT signalling is essential for 
melanocyte development and is associated with melanomas arising on acral, mucosal, and chronically 
sun-damaged skin. Mutations in GNAQ and GNA11, two G protein a subunits involved in MAPK 
signalling, are the dominant genetic lesions in uveal melanomas.. Known melanoma oncogenes and 








Activating mutations of relevant components of the MAPK pathway, such as BRAF and 
NRAS oncogenes have been identified respectively in 63% and 26% of primary melanomas 
71
 The most common mutation in BRAF gene is a missense mutation with a valine-to-
glutamic acid substitution in position 600 (BRAF
V600E
) in the kinase domain that renders RAF 
constitutively active, enabling it to bind its substrate as a monomer and leading to a constant 
MEK-ERK signalling.
71
 NRAS mutations are usually gain-of function alterations [with the 
most common being leucine for glutamine at position 61 ( NRAS
Q61L 
)] that maintain RAS in 
the GTP-bound state, the active form.
72
 Both of these alterations result in MAPK pathway 
hyperactivation.  
Melanoma cells can also be characterized by AKT3 
73
 amplification; insertions and deletions 
in the coding region PTEN 
74





different of its components (including mTOR, IRS4, PIK3R1, PIK3R4, and PIK3R5), leading 
to a constitutive signalling of the phosphatidylinositol 3-kinase pathway. 
75,76
 
Moreover, the receptor tyrosine kinase (RTK) c-Kit is activated by somatic mutations in 17% 
of melanomas from chronic sun-damaged skin, and in 11% of acral and 21% of mucosal 
melanomas and it can signal through both the MAPK and the PI3K/AKT pathway. 
77
 
Cutaneous melanomas may also constitutively express several RTKs such as EGFR, 
PDGFR, AXL and VEGFRs , whose activation by autocrine or paracrine mechanisms can 




Furthermore, mutation in NF1 gene determine loss of the GTPase activating protein, causing 




Cell cycle and proliferation regulators 
 
Deletions or mutations in CDKN2A or TP53, as well as amplifications in MDM2, can 
determine loss of cell cycle checkpoint function. Moreover, the RB pathway can be altered 
due to p16INK4a lesions or mutations in either CDK4 or retinoblastoma 1 (RB1), as well as 




Transcription factors and epigenetic regulators 
 
The melanocyte specific transcription factor MITF, can be amplified in many melanomas and 
act as a lineage-specific oncogene; furthermore,  germ-line variants that induce constitutive 
activity are associated with familial melanoma. 
81
 
The main target of MITF, the oncogene MYC, can also be amplified, inducing an activation 
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1.4 TARGET-SPECIFIC INHIBITORS in MELANOMA 
 
The discovery, by Davies et al in 2002 
71
 that 40% - 60% of melanomas carry a 
somatic missense mutation in BRAF gene, has prompted the development of a large number 
of small molecule inhibitors specific for BRAF mutant, and, some years later, for other 
molecules along the MAPK or the PI3K pathways. 
 
1.4.1 FDA- approved drugs 
 
The first inhibitor to be clinically tested was Vemurafenib (PLX4032), a selective 
BRAF V600E inhibitor which in an initial phase I study in melanoma patients led to a 
response rate of 81% 
82
  impressive results that were then confirmed in a randomized phase 
III clinical trial were OS at 6 months was 84% in the vemurafenib group and 64% in the 
dacarbazine group, while the progression free survival (PFS) rates were 5.3 versus 1.6 
months 
83,84
 Due to these striking data, in 2011 the Federal Drug Agency (FDA) approved 
the use of Vemurafenib for the first-line treatment of BRAF mutant melanomas. 
Further studies led to the development and testing of other target-specific inhibitors: 
the BRAF inhibitor Dabrafenib (GSK2118436) and the MEK1/2 inhibitor Trametinib 
(GSK1120212). Phase II and III clinical trials showed improved response rates of both these 
compounds if compared to chemotherapy with increment in both median PFS and OS. 
Specifically, Dabrafenib reached an increment in median progression free survival from 2.7 
months of dacarbazine group to 5.1 months 
84
. Moreover, in patients with BRAF V600E or 
V600K mutant metastatic melanoma, Trametinib, as compared with chemotherapy, 
improved rates of both progression-free (4.8 vs 1.5 months) and overall survival (81% vs 
67% at six months). 
85
 
As a consequence of these results between 2012 and 2013 Dabrafenib and Trametinib were 
approved by FDA for melanoma treatment.  
Starting from the demonstration of efficacy of the BRAF inhibitors Vemurafenib and 
Dabrafenib  and the MEK inhibitor Trametinib as monotherapies for the treatment of 
metastatic melanoma, more recent studies have explored the activity of the combination of 
BRAFi with MEKi in BRAF mutant melanomas in the hypothesis to improve clinical outcomes 
by preventing or delaying the onset of resistance observed with single therapy regimens.
86
 
A study from Larkin 
87
 et al. published last year demonstrated a significant improvement in 
progression-free survival (12.3 vs 7.2 months) of patients with BRAF mutant metastatic 
melanoma by the combination of Vemurafenib with the MEK inhibitor Cobimetinib, paralleled 
by a non-significant but present increment in treatment-related adverse events.
88
 
In a more recent open-label, phase 3 trial conducted on previously untreated patients with 
BRAF V600E or V600K mutations, the association of Dabrafenib and Trametinib significantly 
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improved overall survival compared with Vemurafenib monotherapy and no increased overall 
toxicity was seen. 
89
 
Based on these results, in November 2015, the FDA approved the MEK inhibitor 
Cobimetinib for BRAF mutant metastatic melanoma in combination with Vemurafenib. 
Nevertheless, despite impressive clinical benefits the onset of intrinsic or acquired 





1.4.2 Compounds in pre-clinical and clinical testing 
 
Besides to the FDA-approved drugs, many novel inhibitors of RAF, MEK1/2 and 
PI3K/mTOR are being tested in a lot of of pre-clinical and clinical studies. (Figure 9) 
 
RAF inhibition  
 
Among the novel ATP-competitive RAF inhibitors  that are undergoing evaluation in clinical 
trials there are:  
Encorafenib (LGX818): highly potent BRAF inhibitor with specificity against the 
BRAF V600E. Monotherapy with Encorafenib is currently being tested in a phase I clinical 
trial on patients with advanced or metastatic BRAF
V600E
 melanoma (NCT01436656), while 








 selective RAF inhibitor with potent 
in vivo antitumor activity against several human tumor models. 
91
 A phase I study to 
determine the safety, tolerability, pharmacodynamics and bioavailability was undertaken in 
48 patients with advanced solid tumors including melanoma.
91
 
RAF265: small-molecule multi-kinase inhibitor against multiple kinases, including 
BRAF
V600E
, CRAF and others. 
92
 A phase Ib clinical trial combining RAF265 with the MEK1/2 
inhibitor MEK162 has been completed (NCT01352273) and a phase II clinical trial is ongoing 





MEK inhibition  
 
There are two major classes of MEK inhibitors, ATP competitive and non-competitive 
inhibitors (see Table 4 for a complete list of currently tested molecules). 
Most of the currently used compounds are the so-called noncompetitive MEK inhibitors, 
indicating that instead of competing for the binding to the ATPbinding site, they go to an 
adjacent allosteric site, achieving a high specificity.
94
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Among the more promising second and third generation inhibitors that are being developed 
for MEK1/2 targeting  and that are already tested in phase III clinical trials  there is 
Selumetinib (AZD6244) by AstraZeneca.  
Selumetinib is a highly selective, ATP non-competitive inhibitor of MEK1/2 with no 
activity on other kinases; several pre-clinical studies showed that AZD6244 effectively 
reduced the growth of melanoma cells by inducing G1-phase cell cycle arrest.
95,96
 
 Selumetinib has been tested in phase I clinical trials and its administration resulted 
in disease stabilization and ERK phosphorylation reduction in tumor biopsies of patients with 
metastatic melanoma. 
97
 In a phase II trial, therapy with selumetinib or temozolomide was 
given to metastatic melanoma patients with unknown NRAS/BRAF status; despite results 
showed no significant differences in PFS, all the patients that responded had BRAF mutant 
tumors. 
98
 Further studies, therefore, selected patients with BRAF mutant melanoma and in a 
randomized phase II clinical trial, the combination of dacarbazine and Selumetinib showed 
an improved median PFS if compared to dacarbazine monotherapy (5.6 vs 3.0 months) but 
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PI3K-AKT-mTOR inhibition  
 
Many human cancers have been successfully treated with agents that inhibit mTOR; 
99
 in 
melanoma PI3K signalling targeting has been tested with either first generation agent 
rapamycin and the second-generation agents, everolimus and temsirolimus. 
100
 
Unfortunately, clinical trials with these compounds have shown no objective responses 





All these molecules inhibit mTORC1 and their efficacy is limited due to lack of activity on 
mTORC2. To face this issue both dual mTORC1/2 and dual PI3K-mTOR inhibitors (NVP-
BEZ235) are been tested. 
103
 Both in vitro and in vivo studies have demonstrated that dual 
PI3K-mTOR inhibition has a remarkable anti-proliferative activity and exerts a durable 
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1.5 MECHANISMS OF RESISTANCE TO TARGET THERAPIES 
 
Despite impressive clinical results obtained by FDA-approved drugs such as 
Vemurafenib, Dabrafenib, Trametinib and Cobimetinib, alone or in combinations, there is still 
a significant percentage of patients that do not respond to these inhibitors, used either in 
monotherapy or in combined treatments. Moreover, quite rapid relapses (within 6 months 
from the starting of treatment) are seen not only in patients undergoing single treatments, 
but also for the two-drugs combinatorial regimens. 
82-85,87-89
 
A high number of studies have been carried on to define mechanisms of resistance 
to target-specific therapies (mainly with BRAF V600E and MEK inhibitors), and according to 
its temporal occurrence, therapeutic resistance can be classified in either primary, or 





Figure 1.8: Mechanisms of therapeutic resistance to kinase inhibitors. 
 
 
1.5.1 Intrinsic resistance 
Primary or intrinsic resistance is defined as a lack of treatment response that is seen 
early at starting of treatment. It can be mediated by either tumor intrinsic factors (i.e.genetic 
alterations within the drug target) and by patient-specific factors. 
Melanoma intrinsic resistance to target-specific therapy is not infrequent: 10% to 20% of 
patients never achieve meaningful responses, showing no tumor shrinkage or only limited 
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Melanoma insensitivity to therapies has been linked to alterations in molecules belonging to 
the pathway of programmed cell death with both defects in proapoptotic signalling and 




Moreover, interesting recent studies have addressed the question of whether 
molecular features of the subset of intrinsically-resistant melanomas might mediate 
insensitivity to MAPK inhibition.  In 2013 Garraway et al demonstrated that a dysregulation of 
a melanocytic signalling network that comprises GPCR/PKA/AC and MITF can cause 
resistance to RAF/MEK/ERK inhibition.
110
 Moreover, in BRAF mutant melanomas, a low 
MITF expression and activity and higher levels of NF-kB and of the receptor tyrosine kinase 
AXL have been linked to resistance to MAPK pathway inhibitors. 
111
 
Furthermore, a low MITF/AXL ratio has been proved to predict resistance to several target-
specific therapies both in BRAF mutant and NRAS mutant melanoma cell lines. 
112
 
Of note, parallel oncogenic pathway activation due to mutations in BRAF, RAS, or MEK1 is 
an reason of intrinsic resistance to inhibitors for either MEK1/2 or BRAF mutant respectively. 
 
1.5.2 Acquired resistance 
When disease progresses after an initial response to the targeted therapy, there is 
usually a development of acquired resistance, implying that the tumor has refined a 
mechanism of “escape” to evade blockade of the target.  
As already explained, melanoma acquired resistance to target-specific inhibitors is a major 
hurdle in melanoma therapy because, despite good percentage of initial response, quite all 
patients relapse within 5-7 months. 
82-85,89
 
Several mechanisms of acquired resistance to RAF inhibition have been elucidated and can 
be classified in a MAPK-dependent resistance, which all involve a re-activation of the MAPK 
signalling; a MAPK-independent resistance through the activation of other parallel signalling 




MAPK-dependent resistance is characterized by a re-activation of ERK signalling 
that can be RAF dimerization -dependent or -independent. 
To the first group belong mechanisms that involve secondary BRAF alterations, such as the 
amplification of the number of BRAF copies 
114
, the expression of alternatively spliced 
variants 
115
 of BRAF that dimerize in a RAS-independent manner, as well as acquired RAS 
mutation (i.e. NRAS Q61K) 
113
, identified both in inhibitor-resistant cell lines and in clinical 
samples, or CRAF overexpression.   
RAF- independent mechanisms of resistance include mutations either in MEK1 or MEK2 
116
; 
over expression of other MAPKs, such as COT 
117
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MAPK-independent mechanisms of resistance, on the other hand, bypass the re-
activation of ERK signalling through, for example, activation of the PI3K/AKT pathway
113,119
, 
RTK activity upregulation, as well as repression of important apoptotic BH3-only genes such 
as Bim-EL and Bmf. 
Of note, not all acquired resistance to MAPKi can be explained by genomic 
mechanisms and a recent paper from Hugo et al. 
120
 demonstrated a high recurrence of 
trascriptomic alterations in melanoma resistant to single drug (BRAFi) or duble drug 
therapies (BRAFi+MEKi), specifically with a enhanced c-MET and a reduced LEF1 
expression, as well as with a YAP1 signal activation. 
121
 
1.5.3 Overcoming melanoma resistance to targeted therapies 
 
The majority of the inhibitors used for the treatment of metastatic melanoma (i.e. 
MEK and BRAF
V600E
 inhibitors) achieve anti-tumor effects inducing cancer cell death, mainly 
through the modulation of several molecules in the apoptotic cascade.
122,123
 
Based on this knowledge, on the notion of the interplay between the MAPK and the PI3K 
pathways and on the recently elucidated mechanisms underlying melanoma acquired 
resistance to target-specific inhibitors, many pre-clinical studies have been conducted to 
explore whether an option to overcome primary and secondary resistance to cell death could 
be represented by combinations of multiple anti-tumor agents. 
The most promising drug associations tested at pre-clinical level include (extensively 
reviewed in 
124
 ):  
I) simultaneous targeting of two components of either the MAPK or the PI3K cascades 
II) parallel targeting of MEK and PI3K/mTOR pathways;  
II) RTKs blockade combined with other pro-apoptotic strategies;  
III) death receptors activation in association with MEK-, PI3K/mTOR - or histone deacetylase 
(HDAC)-inhibitors; 
IV) simultaneous targeting of multiple anti-apoptotic molecules. 
Probably, the most successful drug-combination tested has been the association 
between BRAF inhibitors (such as Vemurafenib or Dabrafenib)  and MEK inhibitors like 
Selumetinib, Trametinib or Cobimetinib. The simultaneous treatment of melanoma cell lines 
or xenografts with associations of these drugs leaded to reduced proliferation, tumor growth 
inhibition and increment in cancer cell apoptosis. 
125,126
 
Another promising approach is represented by the simultaneous inhibition of MEK and 
PI3K/mTOR pathways. Several studies have analyzed effects of the combination between 
MEKi and BRAFi (i.e. Selumetinib, Dabrafenib, Trametinib, U0126) with compounds 
targeting PI3K or mTOR (i.e. Wortmannin, BEZ235, AZD8055, Rapamycin). In vitro and in 
vivo testing confirmed beneficial results in terms of reduction in tumor cell viability, increment 
in cancer cell apoptosis and reduce tumor incidence/growth. 
127,128
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1.6 TRAIL: A TUMOR-SELECTIVE, PRO-APOPTOTIC LIGAND 
 
Tumor necrosis factor (TNF) related apoptosis inducing ligand, also known as TRAIL, is a 
type II transmembrane protein of 32-33 kDa that was initially cloned based on its homology 
with FasL/Apo1L/CD95L e TNF. 
129
  TRAIL gene maps on chromosome 3, in position 3q26 
and it is formed by 5 exons and 4 introns. 
130
 
TRAIL is expressed as a 281 amino acids long transmembrane protein with a short 
intracellular domain (N-terminal) of 17 amino acids, an hydrophobic transmembrane portion 
of 21 aa and the carboxi-terminal region (C-terminal) that, following proteolytic cleavage, can 
form the soluble and biologically active form (sTRAIL). 
130
 
TRAIL  is a pro-apoptotic member of the TNF superfamily of death receptor ligands  and acts 




At physiological level TRAIL protein is mainly expressed as a membrane-bound molecule by 
immune cells, specifically by CD4
+
 T cells, monocytes, and dendritic cells. 
132-134
 It plays a 
key role on NK or T-cell mediated killing of infected or tumor cells. TRAIL can be up-
regulated on immune cells by interferon (INF-2 and INF-), interleukin-2 (IL-2) and IL-15 
135
 
and its role in melanoma surveillance is confirmed by studies showing that it can mediate in 





1.6.1 TRAIL receptors  
 
TRAIL has a complex system of receptors, each with a different affinity for the ligand and 
different ability to transduce the associated signal. 
Five receptors for TRAIL are known: TRAILR1/ DR4/APO-2, TRAIL-R2/DR5/TRICK2/Killer, 
TRAILR3/DcR1/TRID/LIT, TRAILR4/ DcR2/TRUNDD and osteoprotegerin (OPG); all codified 
by genes mapping on chromosome 8.
136
 
TRAIL receptors belong to the Tumor-necrosis factor receptor (TNFR) family and four of 
them are type I transmembrane proteins, while OPG is a soluble protein. All receptors share 
common features: the ligand binding sites have 65% of sequence homology and they all 
bind the ligand through two specific sytes: the CDR3, conserved in all the family components 




Two of the receptors, the DR4 (TRAIL-R1) and DR5 (TRAIL-R2), are transmembrane 
proteins with a cytoplasmic “death domain”  (DD) that share with other family members (such 
as Fas/CD95 and TNFR1) and that is responsible for the activation, upon ligand binding, of 
the apoptotic machinery. 
DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), on the other hand, are known as decoy receptors 
(DcRs), and behave as antagonist receptors: while DcR2  has an incomplete DD, the DcR1 
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completely lacks the cytoplasmic region, rendering them, therefore, not able of triggering 
apoptosis. The fifth receptor, osteoprotegerin is a soluble protein with lower affinity for 
TRAIL, with no known pro-apoptotic potential lacking all the cytoplasmic region. 
136
 The role 
of DcRs is still controversial: they are thought to  compete with the pro-apoptotic TRAIL 
receptors for  ligand binding but they have also been shown to be able to activate cell 
survival pathways through NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells), 
ERK or p38 activity. 
138,139
 
Altered expression of TRAIL-R is frequently observed in tumors, but contrasting results have 
been obtained when correlation between TRAIL receptors expression and tumor 
susceptibility to TRAIL and tumor stages has been evaluated 
140,141
 
Of note, in melanoma cells some studies have found a correlation between the level of 
expression of the death receptors and levels of apoptosis in response to TRAIL
142
: higher 
levels of TRAIL-R2 were usually present in more susceptible cells.
143
 
Interestingly, freshly isolated melanoma cells have been found relatively resistant to TRAIL-
induced cell death, and this was associated with a low expression
 
of TRAIL receptors  
 
1.6.2 TRAIL -induced signalling pathways 
 
The mechanism of TRAIL dependent apoptosis induction is a well-characterized pathway 
whose cascade of events corresponds to the “classical” extrinsic (death receptors-
dependent)  pathway of apoptosis. 
144
 
After engagement of DR4 or DR5 by TRAIL, the receptors homotrimerize and this in turn 
induces the aggregation of the death domains, that mediate the recruitment at the plasma 
membrane  of the adaptor protein FADD (Fas- associated Death Domain).
145
 The Death 
Effector Domain of FADD recruits the pro-caspase-8 in its inactive form, allowing the 
assembly of the death-inducing signalling complex (DISC). In the DISC, pro-caspase 8 is 




Two different mechanisms of response to TRAIL have been identified in distinct cell types. 
Accordingly, cells are classified as type I or type II. The TRAIL-DISC chain of events in type I 
cells is able to recruits a high number of initiator caspases (caspase -8 and -10) and is 
sufficient to activate apoptosis program through the cleavage of other downstream 
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Figure 1.9: Intrinsic and extrinsic apoptosis pathways.   
 
In type II cells, on the contrary, the response to TRAIL requires amplification of the 
extrinsic signal by activation of the intrinsic (mitochondrial - dependent) apoptosis 
pathway.
147
 In these cells, initiator caspases cleave the pro-apoptotic BCL-2 family protein 
BH3 interacting-domain death agonist (BID) through the cleavage af its inactive form (p22) to 
a truncated and active t-Bid. After cleavage, the activated BID translocates to the 
mitochondrial membrane, where it interacts with the pro-apoptotic Bcl-2 family members 
BAX and BAK 
148
, allowing these proteins to form pores and to induce MOMP 
(permeabilization of the mitochondrial membrane) 
147
. MOMP promotes the release of the 
pro-apoptotic proteins cytochrome c (cyt-c) , of the Second Mitochondrial -Derived Activator 
of Caspase (SMAC/DIABLO), and of tha Apoptosis Inducing Factor (AIF). 
At this level apoptosis can be regulated through the activity of several molecules, 
among which anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-XL, Mcl-1, Bcl2-A1 and Bcl-w) 
that inhibit the activity of Bax and Bak, and pro-apoptotic regulators such as the BH3-only 
proteins Bim, Bik, Bad, Bid, Bmf, Puma, Noxa and Hrk. 
149
 
In the cytosol, cyt-c and Apaf-1 (Apoptotic protease activating factor-1) bind and recruit pro 
caspase -9, forming a complex known as Apoptosome. 
150
 Inside the apoptosome the pro 
caspase-9 is activated and in turn it activates effector caspases -3 and -7. Among the 
multiple targets of caspases activity there is PARP (Poly-ADP-ribose Polymerase), an 
enzyme with key roles in the DNA repair. 
146
 
SMAC/DIABLO promotes apoptosis by inhibiting the binding between caspases and the IAP 
[cellular inhibitor of apoptosis (cIAP)-1, cIAP-2, X-linked inhibitor of apoptosis (XIAP), 




Another important, regulator protein at the DISC level is the FLICE-like inhibitory protein (c-
FLIP) that can inhibit activation of caspases-8 and -10. 
151
 c-FLIP has three splicing variants 
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that generate 3 isoforms with different molecular weight: c-FLIPS (26KDa), c-FLIPL (55KDa) 
and the c-FLIPR (24KDa). 
Moreover, caspases activity can be directly inhibited by other intracellular molecules such as 




NON APOPTOTIC TRAIL SIGNALLING 
In addition to the canonical apoptosis pathway, TRAIL binding to its receptors was 
recently shown to trigger the formation of a secondary complex that can activate different 
signalling pathways such as JNK, p38 or NF-κB and that results in non-apoptotic stimuli 
152
.Upon TRAIL binding, TRAIL-R1 and TRAIL-R2 receptors can recruit the protein RIP 
leading to formation of a secondary complex, different from DISC and containing TRAF2 and 
TRADD. RIP phosphorylates and activates IkB-kinase (IKK); this in turn leads to IkB 
phosphorylation and degradation that result in release and activation of transcription factor 
NF-kB. The secondary complex is even responsible for the activation of additional pathways 
by TRAIL, including MAPK, JNK and Akt/PKB signalling 
152
. Although not fully understood, 
signalling from the secondary complex through these different pathways, contributes in 
different cell types to regulation of several functions, including proliferation, cell migration, 




1.6.3 TRAIL: a promising anti-tumor agent 
 
Normally, DNA damage induces the apoptotic cascade through the activation of the onco-
suppressor protein p53, whose alterations concur in tumor onset and resistance to therapies. 
For this reason the death receptors represent an appealing therapeutic target, being able to 
activate the programmed cell death program.
143
 
Interest for TRAIL therapeutic potential came from the demonstration that injection of soluble 
TRAIL in animals with different tumor xenografts induced tumor regression with no apparent 
systemic toxicity
140,141
 that instead characterized the usage of other members of the TNF 
superfamily (like Fas/FasL and TNFα/TNFR1). Pre-clinical and clinical studies are currently 






Despite some encouraging results in selected malignancies
154
, a major limitation to the 
targeting of TRAIL pathway is represented by resistance. 
TRAIL pathway has been pre clinically and clinically targeted through recombinant 
soluble forms of TRAIL (developed by Genentech , USA and Amgen, USA) or with 
monoclonal antibodies targeting TRAIL receptors (i.e. Mapatumomab, Conatumomab, 
Lexatumomab). 
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Mapatumomab (Human Genome Sciences, USA) is a fully human agonistic monoclonal 
antibody directed against TRAIL-R1 and it is in phase II clinical trial on non-small lung 
cancer patients and colorectal cancer patients.
155
 
Conatumomab, Laxatumomab (HGS-ETR-2) are instead agonistic antibodies for the TRAIL-




1.6.4 Mechanisms of resistance to TRAIL -induced apoptosis 
 
Different type of cancers, including melanoma, display frequent resistance to TRAIL, 
achieved through several mechanisms. 
The level of expression of the agonist receptors (and of the decoy receptors) is key one 
determinant of susceptibility/resistance to TRAIL in cancer cells, together with the extent of 
expression of the initiator caspase-8. Indeed, some TRAIL resistant melanoma cells have 
been shown to have low levels of DR4 and of caspase-8.
157
 
Moreover, one of the main mechanisms of resistance to TRAIL acts at the level of the DISC 
and is mediated by the cellular FLICE-inhibitory protein (c-FLIP). Indeed, c-FLIP has 
structural homology with pro-caspase-8 and its structure allows it to be recruited to the DISC 
where it inhibits the processing and activation of pro-caspase-8. c-FLIPL and c-FLIPS  can 
compete with pro-caspase-8 for association with FADD 
158
 and  c-FLIP is thus considered a 
major inhibitor of the extrinsic pathway of apoptosis. 
Furthermore, another key determinant of resistance to TRAIL, in melanoma and other 
tumors, is the expression of a large set of anti-apoptotic proteins. For example, an 
overexpression of XIAP can block the activation of effector caspase-3. 
149
  
In several tumor types, including melanoma, constitutive or receptor-induced activation of 
MAPK and PI3K pathways promotes TRAIL resistance. The different mechanisms linking 
signalling pathways activation to TRAIL resistance share a common strategy:  MAPK or 





 Some examples: IGF-1 can trigger resistance to TRAIL by upregulating 
expression of anti-apoptotic proteins Bcl-2, Bcl-XL and surviving. 
159
 In nasopharyngeal 
carcinoma, inhibition of Akt with LY294002 prevents upregulation of FLIP expression and 
rescue TRAIL susceptibility
161
. In melanocytes, stem cell factor (SCF), a melanocyte growth 
factor that activates both the PI3K and the ERK pathways, is protective for TRAIL-induced 
apoptosis 
162
 In neuroblastoma cells, the PI3K/AKT inhibitor PI103 rescues TRAIL 
susceptibility by shifting the balance toward proapoptotic Bcl-2 family members and 
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1.7 ANGIOGENESIS AND ANGIOGENIC SIGNALLING PATHWAYS 
 
Angiogenesis is a complex process that consist in formation of new capillaries from pre-
existing vassels, requiring interaction between cytokines, growth factors, the extracellular 
matrix and different type of cells; angiogenesis is fundamental for tissue maintenance, 
development and survival. 
164
 
Hypoxia is one of the key drivers of angiogenesis because cells respond to reduced levels of 
oxygen stimulating the Hypoxia-inducible factors (HIFs) and other molecules (including 
mTOR) that respond promoting the formation of  new vascuature to guarantee oxygen 
supply. 
165
 During the angiogenic process endothelial cells interact with pericytes, stromal 
cells and the extracellular matrix. 
Endothelial cells respond to hypoxia inducing HIF-1a, which in turn upregulates the 
expression of endothelial growth factor A (VEGFA) and vascular endothelial growth factor 
receptor 2 (VEGFR2). VEGFA binds to two tyrosine kinase receptors: VEGFR1 and 
VEGFR2 stimulating endothelial cell mitogenesis and vascular permeability and resulting in 




Besides the interaction between VEGF and VEGFR families, other pathways known to play 
important roles in the angiogenic process are  the Notch pathway, the Platelet-derived 
growth factor (PDGF) pathway, the angiopoietin (ANGPT1 and ANGPT2) and TIE2/TEK 
interactions, and the transforming growth factor  (TGF ) activity on its receptors. All of 
these pathways and the molecules that they include concur at inducing a remodeling of the 
extracellular matrix, recruitment proliferation and maturation of pericytes and endothelial 
cells. 
Tumor angiogenesis is based on processes similar to the one of physiological angiogenesis, 
both driven by hypoxia, but in case of neoplastic cells, with a persistent stimulation of the 
angiogenic cascade by tumor-produced pro-angiogenic factors. 
164
 
For instance, while ANGPT-2 normally antagonizes activity of ANGPT-1 on TIE2, in tumor 
contexts ANGPT-2 can mediate the recruitment of TIE2-expressing tumor-associated 
macrophages (TEM) that can produce pro-angiogenic factors. 
167
 
Moreover, tumor vessels are different from normal ones, being more disorganized, leaky and 




Melanoma is an highly aggressive disease and its progression from the initial phases to the 
more invasive vertical growth phase is paralleled by the acquisition of a rich vascular 
network. Melanoma neovascularization has been correlated with overall survival, poor 
prognosis and increased relapse rates.
169,170
 
Secretion by melanoma cells of various pro-angiogenic cytokines, such as VEGF-A, PGF-1 
and -2, IL-8, or TGF-1 promotes the so-called “angiogenic switch”, meaning the particular 
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state of the tumor in which the balance between pro-angiogenic molecules and inhibitors is 
impaired in favor of the first. 
171
 
Moreover, HIF1 expression and activity is increased in melanoma and is associated with a 
decreased differentiation of melanoma cells, as well as with VEGF expression (14). 
Furthermore, in melanoma cells, BRAFV600E can concur to stabilize HIF1, the most 
important subunit of HIF1
172
. Furthermore, also the PI3K pathway is involved in an up-
regulation of HIF1 activity through the ribosomal S6 kinase 1 
173
 and an accumulation of 
HIF1 can depend on an increase of reactive oxygen species (ROS) or NF-B. 
174
 HIF1A is 





1.7.1 TRAIL and angiogenesis 
 
Several studies have previously reported the possible anti-angiogenic effects of TRAIL in 
both the soluble and the membrane-bound form. In 2010 Easton et al 
176
 demonstrated the 
inhibition of angiogenesis exerted by TRAIL through the induction of vascular endothelial 
apoptosis. Moreover, in a study published by Carlo-Stella et al., intravenous injection of 
mTRAIL-expressing CD34
+
 cells exerted a potent antitumor activity in NOD/SCID mice 
bearing systemic multiple myeloma and non-Hodgkin lymphoma xenografts 
177,178
. This was 
due to an efficient homing of CD34+-TRAIL+ cells to the neoplastic tissue where these cells 
induced a significant anti-tumor activity thanks to the disruption of the tumor vasculature, as 
evidenced by endothelial cell apoptosis and hemorragic necrosis. These effects were 
observed only in the tumor-associated vasculature. Interestingly, a recent study by Wilson et 
al. 
179
 has provided evidence for the mechanism of the selective effect of TRAIL on tumor-
associated endothelial cells. In fact, only these cells, and not the endothelial cells found in 
normal tissues, upregulate the TRAIL receptor DR5 and become susceptible to apoptosis by 
TRAIL 
179
. Furthermore, Wang et al demonstrated cooperation between TRAIL and 
doxorubicin to reduce microvessels density through a reduced production of the pro-
angiogenic IL-8 and an increment in the anti-angiogenic factor CXCL10 in an in vivo model 
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1.7.2 MAPK and PI3K cascades: role in angiogenesis and endothelial 
cell function 
 
Both the MAPK and the PI3K/AKT/mTOR cascades exerted a central role in the biology of 
endothelial cells 
181
:   signalling from these pathways is required to prevent endothelial cell 
apoptosis, as well as to promote angiogenesis and cell survival 
181
.  
Several studies have demonstrated the importance of the PI3K/AKT/mTOR cascade in 
regulating the VEGF expression and activity. Specifically: Ras expression increases VEGF 
expression through PI3K activity 
182
; and the activation of MEK and PI3K signal has been 
shown to contributes to IL-8 and VEGF expression in head and neck squamous cell 
carcinoma 
183
 and of VEGFR1 and VEGFR3 on bone marrow endothelial cells. 
184
 
Moreover, Akt has been shown to induce the phosphorilation of the endothelial Nitric Oxyde 




Furthermore, the modulation of pro-angiogenic factors, such as HIF-1, has been 
demonstrated to be a consequence of  AKT activity
186
 and the importance of the RAS-RAF-
MEK-ERK signalling and the PI3K pathway in melanoma angiogenic switch and aggressive 
phenotype has been confirmed by a recent study 
187
 demonstrating that expression of GAB2 
and consequent activation of the PI3K cascade induced an incremented angiogenic 
response through the up-regulation of HIF-1α and VEGF levels in NRAS-driven melanoma 
cells. Moreover, in the same experiments, the MEK inhibitor PD325901 was able to 
suppress this pro-angiogenic activity. 
AKT activation is known to phospholylate the oncoprotein HDM2, which, consequently 
translocates from cytoplasm to nucleus, process that is inhibited by PI3K/AKT pathway 
blockade. On the contrary, AKT overexpression or PTEN loss induce an increment in the 
expression of HDM2 and HIF-1further confirming the role of molecules belonging to the 
PI3K pathway in the regulation of the HIF activity. 
186
 
Lastly, a forced expression of PTEN is able to inhibit embryonic angiogenesis and a 




Also, in hypoxic conditions, the MAPK signalling pathways promotes expression of Bcl-2 in 
endothelial cells, which in turn promotes angiogenesis, and a MAPK inhibitors blocks Bcl-2 
induction in such cells
188
. Similarly, treatment of endothelial cells with the association of 
mTOR inhibitors and MAPK inhibitors can reduce endothelial cell survival, proliferation, 




Of note, several inhibitors of either the PI3K or the MAPK pathways, used alone or in 
combinations with other drugs, have been associated with anti-angiogenic effects on tumor 
models of different type of malignancies: the combination of Sorafenib and Selumetinib 
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obtained a reduced angiogenesis in renal cell carcinoma xenografts 
190
 a combined MEK 
and VEGFR inhibition resulted in an enhanced inhibition of tumor angiogenesis in lung 
cancer models. 
191
 Similarly, a combination of AZD6244 and BEZ235 enhanced the anti-
angiogenic effects of monotherapy through the reduced expression of matrix 
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Metastatic melanoma is an aggressive disease, often resistant to therapies. Despite 
impressive clinical results achieved in the past 5 years, mainly due to the testing and 
consequent FDA- approval of target-specific drugs and, more recently, of immune check-
point inhibitors, a significant portion of patients is characterized by intrinsic resistance to 
therapy or experience quite rapid relapses after initial response.  
Innovative and effective strategies are therefore needed to overcome insensitivity or 
resistance to different anti-tumor agents and several preclinical studies have explored the 
possibility of combinatorial approaches associating pathway- or target-specific inhibitors. 
 
Since apoptosis is a key process involved in the elimination of potentially altered cells, 
aberrant regulation of apoptosis represents a critical hallmark in cancer, allowing the survival 
of neoplastic cells. Deficiency in the programmed-cell death control is also at the basis of 
melanoma chemotherapeutic resistance and a common goal in cancer treatment is 
represented by induction of apoptosis in tumor cells.
109
  
Moreover, effective strategies for cancer treatment should be aimed not only at inducing 
cancer cell death, but also at targeting other mechanisms in the microenvironment relevant 
for tumor growth, such as tumor angiogenesis. 
 
TRAIL is a pro apoptotic, vascular- disrupting and tumor- selective agent that has been 
tested for the treatment of different types of malignancies achieving good safety profiles but 
unsatisfying results due to frequent resistance of cancer cell to monotherapy targeting TRAIL 
pathway. 
 
Based on this knowledge, the goal of the present project was to test the anti-tumor efficacy 
in-vitro and in-vivo  of a combinatorial approach  associating TRAIL with inhibitors targeting 
the two main oncogenic signalling pathways often hyperactivated in melanoma cells, the 
MAPK and the PI3K pathways. 
 
As a MEK inhibitor we decided to use Selumetinib (AZD6244), a compound that is in phase 
III clinical trials for treatment of solid malignancies and for the targeting of the PI3K cascade 
we chose NVP-BEZ235 (herein referred to as BEZ235), a dual PI3K-mTOR inhibitor 
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Our working hypothesis was that these agents should have multiple effects on: 
 
1) tumor cells 
exerting synergistic anti-tumor effects possibly combining the pro-apoptotic activities of the 
different drugs used and activating simultaneously both the the extrinsic (mainly through 
TRAIL activity) and the intrinsic (mainly due to the activity of MEK and PI3K pathway 
inhibitors)  apoptosis pathways; 
this approach should be able to overcome melanoma intrinsic resistance to programmed cell 
death and will be tested on a panel of melanoma cell lines with known BRAF, NRAS, PTEN 
and p53 status to evaluate possible dependency of the effects from a specific genetic 
setting. 
 
2) tumor microenvironment 
promoting an anti-angiogenic effect and reducing therefore tumor growth and 
neovascularization, possibly combining the well-known vascular disrupting activity of TRAIL 
and the effects of inhibition of pro-angiogenic pathways in tumor and in tumor-associated 
vasculature due to targeting of ERK and AKT cascades. 
 
Furthermore, since it is well known that tumor-associated vasculature is different from 
physiological vessels, we sought to test the hypothesis that co-culturing melanoma cells with 
endothelial cells could render the latest more susceptible to either target-specific therapy or 
TRAIL and on which mechanistic basis. 
 
The proposed work was therefore aimed at evaluating the in vitro and in vivo activity and 
mechanism of action of TRAIL in association with AZD6244 and BEZ235 inhibitors. 
Expected results should provide a preclinical proof-of-concept for drugs association able to 
















The aims of the project were pursued through four main steps: 
 In vitro analysis of synergism between inhibitors of oncogenic signalling 
pathway and TRAIL  
A large panel of melanoma cell lines (n=49) with known genetic background was 
characterized for susceptibility/resistance profile to small molecules inhibitors 
targeting the MEK and/or PI3K/mTOR cascades and soluble TRAIL. MTT assay was 
used to determine IC50 of each cell line and these data were used to evaluate 
possible co-resistance to the selected drugs. Our findings revealed independent 
susceptibility profile of melanoma cells to AZD6244, BEZ235 and sTRAIL. 
Correlation with known relevant mutations in BRAF, NRAS, p53 and PTEN was 
studied. Chou-Talalay interaction analysis was performed to analyze potential 
synergism of the drugs used in our experiments.  
 
 In vitro analysis of mechanisms behind the synergism 
Genome-wide expression profiling of melanoma cells was performed on Illumina 
platform to get insight into the mechanisms underlying drugs synergism. 
Annexin/Propidium Iodide (PI) staining, protein arrays, Western blot analysis, 
caspase activation and mitochondrial membrane depolarization () evaluation 
were used to confirm hypothesized mechanisms. Transient silencing techniques 
proved the central role of identified molecules.  
 
 In vivo treatment of melanoma xenograft with the MEK inhibitor Selumetinib 
and sTRAIL 
Female SCID mice were subcutaneously injected with exponentially growing 
melanoma cells and mice were treated with AZD6244 and TRAIL at concentrations 
defined based on literature data. Tumor growth rates were compared between 
untreated and treated groups and appropriate statistical analysis was performed on 
growth curves. Treatment-related toxicities were excluded based on haematoxylin-
eosin staining of main organs. Immunohistochemistry staining for significant 
molecules was performed on tumor nodules to define in vivo mechanism of action of 
drug association.  
 
 In vitro modeling of melanoma-endothelium interaction 
HUVEC cells were used to set up co-culture experiments with different melanoma 
cell lines; magnetic separation and multi- parametric flow cytometry was used to 
determine effects of cell-cell interaction on activation, differentiation status of 
HUVEC cells and on their response to combinatorial treatment.  











3. MATERIAL and  
METHODS 
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3.1 REAGENTS 
 
The small molecules inhibitors AZD6244 (MEK1/2), BEZ235 (dual PI3K/mTOR) and 
PLX4720 (BRAFV600E) were purchased from SelleckChem (Houston, TX, USA); soluble 
recombinant human TRAIL from AdipoGen (San Diego, CA, USA). The pan-caspase 
inhibitor z-VAD-fmk and its relative control z-FA-fmk were purchased from R&D Systems 
(Minneapolis, USA). Tetramethylrhodamine ethyl ester (TMRE) was purchased from 
Invitrogen-Life Technologies (Carlsbad, CA, USA). All reagents were formulated as 
recommended by suppliers. 
 
3.2 CELL LINES 
 
Melanoma cell lines were established during several years in the lab starting from surgical 
specimens of melanoma patients (Stage IIIb to IV following American Joint Committee on 
Cancer) not previously subjected to chemotherapy and admitted to Fondazione IRCCS 
Istituto Nazionale dei Tumori, Milan. All lesions were histologically confirmed to be 
cutaneous malignant melanomas. The study was conducted following institutional guidelines 
and in accordance to the Declaration of Helsinki Principles. Melanoma cell lines were 
cultured in RPMI-1640 (Lonza, Basel, Switzerland) supplemented with 2-10% inactivated 
fetal bovine serum (FBS) (Lonza), 2mM L-glutamine (Lonza), 20mM HEPES buffer 
(BioWhittaker, Walkersville, USA) in a humified chamber (95% air, 5% CO2) at 37
o
C. 
Human Umbelical Vein Endothelial Cells (HUVEC) were purchased from Invitrogen-Life 
Technologies and maintained in Medium-200 supplemented with Low Serum Growth 
Supplemented (LSGS) Kit (Gibco-Life Technologies). For all experiments HUVEC were used 
before the 10th in vitro passage.  
All cell lines were regularly screened to ensure absence of mycoplasma contamination by 
PCR Mycoplasma test kit I/C (PromoKine, Heidelberg, Germany) following manufacturer’s 
intructions. 
 
3.3 CELL VIABILITY ANALYSIS 
 
3.3.1 Cell viability  
 
For evaluation of cell viability the with 3-(4,5)dimethylthiazol-2,5-diphenyltetrazolium bromide 
(MTT) assay was performed.  
In details, cells were seeded at appropriate concentration in 96-wells flat bottom plates with 
200 l RPMI 1640 supplemented with 2% FCS. Next day, drugs were added and cells 
treated with different concentrations of AZD6244 (0.001M - 10M), BEZ235 (0.001M - 
10M), recombinant human TRAIL (5-100 ng/ml. Treatments were performed in 
quadruplicates. After 48 hours cultures were evaluated for cell viability, by the MTT assay, a 
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colorimetric metabolic activity indicator of cell viability (it produces a yellow solution that is 
converted to dark blue, water-insoluble MTT formazan by mitochondrial dehydrogenases of 
living cells). Briefly, 20 l of MTT were added to cells and cultures were incubated at 37
o
C 
for 4 hours; after this time, supernatant is carefully removed and 100 l DMSO (Dimethyl 
sulfoxide) added. The plates are then read for absorbance at 570 nm with reference at 630 
nm in a InfiniteM1000 plate reader (Tecan, Männedorf, Switzerland).  
Non-linear regression analysis (by PRISM software, Graphpad) was used to calculate IC50 
values for melanoma response to AZD6244 and BEZ235, based on dose-response curves 
by a log(inhibitor) vs. response, variable slope equation.  
 
3.3.2 Drug interaction analysis  
 
Growth inhibition data from MTT assays, performed after 48h of treatment, were analyzed 
for drug interaction by the Chou and Talalay
193
 method through the CompuSyn software 
(ComboSyn). This is a method for drug combination analysis based on the median-effect 
equation, and comprises the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard 
equations that define interaction between two entities. 
The combination index values (CI) calculated through this mathematic result in a quantitative 
definition of additive effect (CI = 1), synergism (CI < 1) and antagonism (CI > 1) for drug 
associations. Specific algorithms are also used to calculate fraction affected (FA) values for 
each combination of compounds, indicating the percentage of cells affected by the 
treatment.  
 
3.3.3 Assessment of apoptosis  
 
Melanoma cell lines were harvested at exponential growth phase and seeded in 6-weel 
plates at appropriate concentrations in RPMI with 10% FCS. The day after, culture- medium 
was changed and cells were treated with AZD6244 and BEZ235 at 0.05 mM and TRAIL at 
25 ng/ml or as single agents or in combination in RPMI with FCS 4%. Annexin-V APC and 
Propidium Iodide (PI) (BD Pharmingen) were used to detect the extent of apoptosis (early, 
Annexin-V+ PI- and late, Annexin-V+ PI+) and necrosis (Annexin-V- PI+) after 72 hours of 
treatment. Briefly, cells were detached with Trypsin and washed with cold phosphate-
buffered saline (PBS) (BioWhittaker, Lonza, Belgium), resuspended in Binding Buffer (BD 
Pharmingen) and incubated with Annexin-V APC and PI for 15’ at Room Temperature (RT). 
Samples were acquired on a Gallios Flow Cytometer (Beckman-Coulter), cell debris were 
excluded gating on forward scatter (FSC) and side scatter (SSC) and data were analyzed by 
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3.3.4 Measurement of mitochondrial membrane depolarization (m) 
 
The extent of mitochondrial membrane depolarization was determined using the fluorescent 
probe Tetramethylrhodamine Ethyl Ester (TMRE) (Invitrogen, Life Technologies). TMRE is a 
fluorescent dye that penetrates through cell membrane and is accumulated by mitochondria. 
In case of mitochondrial membrane depolarization, the integrity of the mitochondrial 
membrane is disrupted, TMRE is lost and a reduced fluorescence intensity is detected in 
depolarized cells. Cells were seeded and treated as in 3.4.3, then after 48h harvested, 
washed with RPMI and incubated for 15 minutes at 37
o
C with TMRE at final concentration of 
50nM. Data were acquired on a Gallios Flow Cytometer (Beckman Coulter) and data were 
analyzed by FlowJo software gating on forward scatter and side scatter to exclude debris 
and then evaluating the percentage of cell with a reduced MFI if compared to untreated 
samples.  
 
3.4 CASPASE ACTIVITY 
 
3.4.1 Caspase activity detection and inhibition 
 
Caspase-3/7 activation was evaluated using the MUSE cell analyzer (Millipore). Briefly, cells 
were seeded and treated as in 3.4.3 and after 48h the MUSE caspase 3/7 kit was used to 
stain for the activated form of caspases of interest. The function of the kit is based on a 
substrate for caspases 3 and 7: if present in the active form they are able to cleave the 
substrate, that become fluorescent and detectable.  
Instead, caspase-8 activation was detected through intracellular staining with an antibody 
specific for cleaved caspase-8 (Cell Signalling Technologies) after permeabilization of the 
cells with the Fix and Perm solution (BD Biotecnologies); data were acquired on a Gallios 
Flow Cytometer. 
For caspases-inhibition experiments, melanoma cells were seeded as in 3.4.3 and the day 
after, before treatments, pre-incubated for 1 hour at 37
o
C with general caspase inhibitor z-
VAD-fmk or control z-FA-fmk (BD Pharmingen) used at 5 M. Caspases inhibitor and 
relative control were added every 24 hours and extent of apoptosis was then assessed by 
annexin-V/PI flow cytometry assay at 72h from treatments. 
 
3.5 GENOME-WIDE EXPRESSION PROFILING 
 
For gene expression experiments, melanoma cells were seeded at appropriate 
concentration in T75 flasks and, the day after,  treated for 8h with AZD6244 (0.1 M), 
BEZ235 (0.1 M) or TRAIL (25 ng/mL), as single drugs or in combinations. Each type of 
treatment was performed in three biological replicates. Total RNA was then isolated from 
melanoma cells, using QuiaZol (Invitrogen) reagent, and a clean-up treatment with RNAeasy 
kit (Qiagen, Valencia, CA) and with RNase-free DNase to remove contaminating genomic 
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DNA was performed. The Bioanalyzer (Agilent) was used to assess RNA integrity and  
single-color hybridization of the obtained RNAs was performed on Illumina Bead Chip 
HumanHT-12_v4 Microarrays (Illumina San Diego, CA) containing more than 48,000 
transcript probes.  
The expression profiles have been deposited in NCBI’s Gene Expression Omnibus (GEO) 
with GSE accession number GSE55050. The BeadStudio Illumina software was utilized to 
correct for background, filtering of data, and quantile normalization, while the BRB-array 
Tools (Vers.4.3.0) software allowed the identification of group of genes significantly 
modulated by the different types of treatment. Class comparison was carried out by a 
random-variance F-test with a nominal significance level of 0.001 and the permutation P 
values for significant genes were computed based on 10,000 random permutations. 
VENNTURE software
194
 was used to carry on a pairwise analysis of significance of gene 
modulation between any two of the treatments was carried out at P=0.01., and  Edwards-
Venn diagram were generated in order to categorize all genes significantly modulated by any 
of the single-treatment as well as by any combination. Upstream regulator analysis and 
downstream effects analysis on genes significantly modulated by different treatments were 
done using Ingenuity Pathway Analysis (IPA 8.5, www.ingenuity.com); this software is able 
to identify, based on the observed changes in the gene expression, which biological 
functions are expected to be increased or decreased and which modulation in upstream 
transcriptional regulators can explain the differences seen in the dataset. Results are 
displayed based on P values and Z score statistics.  
 P values measures how likely is the association between a set of genes and related 
function, or the likelihood of the overlap between the changes in gene expression in the 
dataset and those that are regulated by a predicted transcription factor. The meaning of the 
Z score statistics is to infer the activation states (“increased” or “decreased”) of the identified 
biological functions and of the predicted transcription factors. Only Z scores greater than 2 or 
smaller than 2 can be considered significant. 
 
3.6 SURFACE AND INTRACELLULAR STAININGS 
 
3.6.1 Flow cytometry experiments 
 
Expression of surface intracellular molecules was evaluated by flow cytometry, when needed 
after cell permeabilization with Cytofix/perm (BD Pharmingen). Briefly cells at exponential 
growth phase were harvested and seeded at appropriate concentrations; the day after 
treated with AZD6244 and BEZ235 at 0.05mM and TRAIL at 25ng/ml as single drugs or in 
combinations. At 24-48 hours cells where then harvested again, washed with cold PBS and 
fixed for 20 minutes on ice with the fixation solution; after the incubation on ice cells were 
washed twice with Perm-wash and stained with appropriate antibody. Flow cytometry 
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analyses were carried out with antibodies specific for: cleaved caspase 8, TRAIL-R1/DR4, 
TRAIL-R2/DR5, CD31(PECAM), CD325 (N-Cadherin) (BioLegend); TRAIL-R3/DCR1 and 
TRAIL-R4/DCR2 (AdipoGene); CD56 (NCAM), CD54 (ICAM-1) (BD Pharmingen), MCSP, 
CD202b (TIE-2), CD144 (VE-Cadherin) (Miltenyi Biotec).  
When needed FITC conjugated goat anti-mouse secondary antibody (Jackson Lab) was 
used. 
 
3.7 PROTEIN ANALYSIS 
 
3.7.1 Protein extraction 
 
For protein extraction a total of about 5x10
6
 cells was seeded in T75 flasks and treated with 
inhibitors or TRAIL at concentrations used for annexin-V/PI experiments. At desired time 
points cells were collected, washed with ice-cold HBSS (BioWhittaker) and homogenized in 
lysis buffer (with PMSF and proteases inhibitor) (Invitrogen) or lysis buffer provided with 
protein arrays (R&D) for 30 minutes on ice. Cells were then centrifuged at high speed and 
supernatants collected for protein analysis. Protein concentrations in lysates were 
determined using BCA Protein Assay Kit (Pierce) according to manifacturer’s instructions. 
 
3.7.2 Western Blot  
 
Cell lysates (30-60 μg) were loaded in precast 7% NuPAGE Tris-Acetate (for Apollon) or 4% 
to 12% NuPAGE Bis-Tris polyacrylamide gels (Invitrogen Life Technologies), for other 
molecules and transferred to nitrocellulose membranes (Amersham). After membrane 
blocking with Tris-buffered saline solution (0.1% Tween-20 (TBS-T) 5% Bovine Serum 
Albumine (Sigma-Aldricht), blots were hybridized overnight with the appropriate primary 
antibody. The next day membranes were washed with T-TBS and hybridized with 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody. Signals were 
detected using  the chemiluminescence method and the ECL Western Blotting Detection 
System (GE Healthcare).  
Antibodies used in Western Blot analysis were: livin, clusterin, cIAP-2, BIM, BID, BAX, Mcl-1 
and c-Myc (Cell Signalling); survivin (Novus Biologicals); c-IAP1 (R&D Systems); HIF1 and 
actin (Abcam); Apollon/BIRC6, XIAP, -SMA (BD Biosciences); cFLIPL/S (Alexis 
Biochemicals). 
 
3.7.3 Protein arrays specific for apoptosis molecules 
 
The Human Apoptosis Array kit (R&D Systems) was used according to manufacturer’s 
instructions using cells and collected as indicated in the specific data sheets. Arrays were 
washed and 50 ng of total proteins were hybridized overnight on the arrays. Signals on 
membranes were detected by chemiluminescence and quantitated by densitometric analysis 
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with Quantity One software (BioRad Laboratories). Values of protein expression are 
calculated as percentage of the relative positive controls mean, after background 
subtraction.  
 
3.7.4 Angogenesis-related protein arrays 
Angiogenesis Array kit (R&D Systems) was performed in accordance to manifacturer’s 
instruction with cell supernatants of treated or untreated cells. Supernatants were collected 
after an O/N of treatment with single drugs or combinations of inhibitors and TRAIL (in order 
to have as less cell death as possible) and then centrifuged to eliminate any cellular debris. 
Signals on membranes were detected by chemiluminescence and quantitated by 
densitometric analysis with Quantity One software (BioRad Laboratories). Values of protein 
expression are calculated as percentage of the relative positive controls mean, after 
background subtraction. To assure culture medium was not responsible for signals seen, a 
control membrane was hybridized with medium-only and developed as the others. 
 
3.8 SILENCING BY SMALL- INTERFERING RNA (siRNA) 
For silencing experiments we used an Apollon-specific siRNA that our lab had previously 
validated (see ref 25) for activity in our melanoma cell lines. The stealth RNAi siRNA 
sequence is GGGCAUGCUGGAAUGUUGACGUUAA (Invitrogen). Cells were seeded at 
appropriate concentration in complete medium in 6-well plates and, the day after, transfected 
with Apollon-siRNA or with its corresponding negative control, at the final concentration of 
75nmol/L. Lipofectamine RNAiMAX (Invitrogen) was used as transfecting agent. After 48h 
from transfection cells were treated with indicated drugs and then evaluated at different time 
points for extent of apoptosis or mitochondrial depolarization. 
 
3.9 ELISA ASSAYS 
TGF1 and VEGF specific Quantikine ELISA kit (R&D Systems) were used according to 
manufacturer’s instructions. Supernatant from treated and untreated melanoma cells were 
collected as in 3.8.4 and stored at -80
o
C until use. Absolute concentration was calculated 
based on a standard curve obtained through serial dilution of a standard sample in the kit. 
The microplate reader (Tecan Infinite M1000) was used to determine optical density of each 
plate and then data were elaborated through Microsoft Excel software. 
 
3.10 ANIMAL EXPERIMENTS  
In vivo experiments were evaluated and approved by the Institutional Ethical Committee for 
Animal Experimentation of our Institute and by the Italian Ministry of Health (Project 
INT_17/2011). Moreover, all projects involving animal experimentation were performed 
according to the Italian laws (D.L. 116/92 and after additions). 
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Immunocompromised female mice (severe-combined immunodeficient mice, SCID) 8-10 
weeks old were purchased from Charles River Laboratories, housed in the facility at our 
institute and provided with food and water ad libitum. Exponentially growing melanoma cells 
were harvested and injected subcutaneously (3 or 5x10
6
) in the left flank of each animal. 
Mice were then checked every two days for sign of tumor growth. Tumor size was regularly 
evaluated by measuring the orthogonal diameters (d and D) and calculating tumor volumes 
with the following formula: 4/3d
2 
D /2.  
For experiments with drugs treatment, after injection mice were randomly assigned to one of 
4 groups (7 animals/group) and when tumors became palpable treatments were started. 
AZD6244 was administered at 25 mg/kg by oral gavage, TRAIL  at 30 mg/kgby 
intraperitoneal injection. Animals received vehicle, the two drugs as monotherapy or their 
combination, 7 days per week for two consecutive weeks. Mice were monitored daily for 
signs of toxicity and were weighed twice a week.  




Immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded 
specimens. 4-μm-thick tissue sections were cut, deparaffinized through graded series of 
ethanol passages and then rehydrated in distilled water. A 30-min incubation in methanol 
with 0.3% H2O2 was used to inhibit endogenous peroxidase and to optimize immune 
detection, nonenzymatic antigen unmasking was performed: tissue sections heated at 95°C 
for 6 min in an autoclave in a 5 mM citrate buffer (pH 6). After cooling, tissue sections were 
incubated with primary antibody overnight at 4°C, then covered with streptavidin–
horseradish peroxidase (DAKO Corp.) for 30 min and finally visualized with the use of red 3-
amino-9-ethylcarbazole (Sigma Chemical) in 0.05 M acetate buffer containing 0.015% H2O2. 
Tissue sections from melanoma metastases were characterized by staining for TRAIL-
R2/DR5 (Sigma).  Neoplastic nodules removed from mice at the end of treatment were 
characterized by staining with mAbs to human pERK, cleaved caspase-3 (Cell Signalling), 
Apollon, HIF1, IL8 (AbCam), VEGF (Santa Cruz Biotechnology), as well as to mouse 
CD31 (Dianova).  Apoptosis extent was evaluated by TdT-mediated dUTP nick end-labeling 
(TUNEL) staining (Roche).  Tissue sections subjected to the same treatment but without 
incubation with primary antibody were used as negative controls. Images were acquired at 
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3.12 MELANOMA-ENDOTHELIAL CELLS CO-CULTURES  
Exponentially growing melanoma cells were irradiated with 5000 CyG and seeded at the 
appropriate concentration in RPMI 10%FCS. After 24 hours, co-culture experiments were set 
up with a 1:1 rate with HUVEC cells in Med200 medium. After 6 days cells were harvested 
and stained with indicated antibodies (as in 3.7.1) or resuspended in ice-cold PBS buffer 
with 2mM EDTA and 0.2%FCS and then purified with magnetic separation using anti-MCSP 
or anti-CD31 microbeads (Miltenyi Biotec) in accordance to manifacturer’s instructions and 
depending on necessities. 
 
3.13 STATISTICAL ANALYSIS 
Cluster 3.0 software was used to cluster data from TRAIL susceptibility, TMRE and caspase-
8 cleavage assays, as well as results of drug interaction analyses.  
GraphPad Prism software was used to generate graphs and statistical analysis for every 
figure. Spearman correlation analysis was used to determine correlation between melanoma 
responsiveness to TRAIL  and susceptibility to target-specific inhibitors or expression of 
TRAIL receptors. 
One-way or Two-way ANOVA, followed by Bonferroni or Student-Newman-Keul (SNK) 
multiple comparison test were used to determine significance of differences among 
treatments in terms of melanoma apoptosis, caspase activation, mitochondrial 
depolarization, modulation of apoptosis- and angiogenesis-related molecules.  
In xenograft experiments, comparison of the antitumor activity of different treatments was 
carried out by mixed effects model ANOVA 
195
 by XLSTAT software (Xlstat). 
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4.1 TRAIL RECEPTORS ARE EXPRESSED BOTH IN MELANOMA CELL 
LINES AND IN METASTATIC MELANOMA LESIONS  
 
To confirm the choice of using the pro-apoptotic molecule TRAIL for our association studies, 
we decided to first evaluate responsiveness to TRAIL in a panel of 49 melanoma cell lines 
isolated in our laboratory from primary and metastatic tumors (Supplementary Table S1 
summarizes known features of cell lines used). 
 
Melanoma response to TRAIL was initially evaluated through MTT assay.  55.6% of cell lines 
were found to be susceptible (>75% inhibition at the highest dose) to the anti-proliferative 
and pro-apoptotic activity of TRAIL, while the remaining 44.4% of cell lines showed strong 
resistance to TRAIL (<25% cell death at 100 ng/mL) (Figure 4.1A). Moreover, 
responsiveness to TRAIL was not associated with presence of the two most frequent genetic 









Figure 4.1: Responsiveness to TRAIL and correlation with genetic background. A) Susceptibility 
and resistance to TRAIL (10-100ng/ml) of a panel of melanoma cell lines tested by MTT assay after 
48h of treatment. Data are reported as % of growth inhibition over untreated controls. B) Lack of 
association between responsiveness to TRAIL and known mutations in BRAF or NRAS genes.  
 
 
We then decided to analyze TRAIL receptors expression both in vitro, on the same panel of 
melanoma cell lines, and in tissue sections from lymph nodes or subcutaneous melanoma 
metastases from 10 patients.  
As shown in Figure 4.2A, the analysis of TRAIL receptor expression indicated that TRAIL-R1 
(DR4) and TRAIL-R2 (DR5) were always expressed in vitro, although with different intensity 
of staining, and levels of expression of DR5 but not of DR4 were significantly (p= 0.0196) 
correlated to the responsiveness to TRAIL, pointing to the relevance of this receptor for the 
pro-apoptotic response to the ligand.  
TRAIL-R2/DR5 expression in tissue samples was confirmed by immunohistochemistry 
staining on neoplastic cells from melanoma metastases (Figure 4.2B), supporting the choice 
of selecting this pathway as a target in human melanoma.  
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Figure 4.2 TRAIL receptors expression and correlation with response. A) MTT assay at 48h on a 
panel of melanoma cell lines treated with TRAIL=100 ng/mL; TRAIL-R1 and -R2 expression was 
assessed by flow cytometry and results are expressed as mean fluorescence intensity (MFI). Statistical 
analysis by Spearman correlation. B) Tissue sections from lymph node (lesions #1-3 and #5-10) or 
subcutaneous (lesion #4) melanoma metastases from 10 patients were stained with anti-DR5 mAb.  
 
 
4.2 INDEPENDENT SUSCEPTIBILITY PROFILES OF MELANOMA CELL 
LINES TO TARGET-SPECIFIC INHIBITORS AND TRAIL 
 
To further confirm the rationale of combining TRAIL with small molecule inhibitors specific for 
oncogenic signalling pathways, we decided to evaluate whether or not human melanoma cell 
lines are characterized by frequent intrinsic concomitant resistance to MEK, PI3K/mTOR 
inhibitors and to the death receptor ligand TRAIL. 
To this end we decided to work on the same panel of 49 patient-derived melanoma cell lines 
with known wild-type or mutant BRAF, NRAS, PTEN and p53 (Supplementary Table S1); to 
best represent the possible different alterations present in human melanoma. We initially 
characterized all cell lines for susceptibility to AZD6244 and BEZ235 by MTT assays using a 
wide range of doses. IC50 for each inhibitor were calculated through non linear regression.  
Our data revealed that numerous tumors responsive (with an IC50 <0.05 M) to AZD6244 or 
BEZ235, were instead TRAIL-resistant (<10% dead cells at TRAIL 100 ng/mL), while several 
tumors resistant to these inhibitors (with IC50 > 0.2 M) showed instead high susceptibility to 
TRAIL (representative data Figure 4.3).  
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Figure 4.3 Independent susceptibility profiles to MEK and PI3K/mTOR inhibitors and to TRAIL. 
Dose-response curves and responsiveness of selected melanoma cell lines to AZD6244, BEZ235 and 
TRAIL assessed by MTT assay after 48h treatment. Data are expressed as % of live cells over 
untreated controls. 
 
Furthermore, Spearman analysis of growth-inhibition data indicated no significant correlation 
between susceptibility to the signalling inhibitors and to TRAIL (Figure 4.3). Indeed, 
concomitant resistance to AZD6244 and TRAIL, or to BEZ235 and TRAIL was found in only 
7 and 10 tumors respectively (open circles and squares in Fig 4.4). The relative sporadic 
presence of cell lines showing cross-resistance to all three drugs supported our choice of 
evaluating their association for melanoma treatment. 
Literature reports that melanoma cells respond to TRAIL receptor engagement as the so-
called “type II cells”, activating not only the extrinsic pathway of apoptosis, but also the 
intrinsic one (mitochondrial dependent).  
On these bases, we decided to complete the characterization of our panel of cell lines 
analyzing caspase-8 cleavage (by flow cytometry) and loss of mitochondrial potential (TMRE 
assay) in response to TRAIL treatment (100 ng/ml, 48h). 
Our data highlighted the expected correlation not only between response to TRAIL (growth 
inhibition by MTT assay) and caspase-8 cleavage (p=0.0086), but also with mitochondrial 
depolarization (p<0.0001, Figure 4.4) confirming that the majority of melanoma cell lines, 
upon engagement of TRAIL receptors, behave as the type-II cells and require amplification 
of apoptotic signals through the mitochondrial pathway. 
Of note, it is well known that small molecules inhibitors, like AZD6244 and BEZ235, are able 
to induce melanoma cell death through the activation of the mitochondrial dependent 
apoptosis cascade. This notion, along with the correlation found between TRAIL 
susceptibility and mitochondrial depolarization, provided also a mechanistic rationale for the 
hypothesis of combining oncogenic and death receptor pathways in human melanoma. 
Targeting melanoma death-resistance pathways 
Results  56 
 
Figure 4.4 Correlation between TRAIL response and mitochondrial depolarization. Cell viability, 
mitochondrial depolarization and caspase-8 cleavage in response to TRAIL and responsiveness to 
AZD6244 and BEZ235 (by MTT assay, 48h). Data clustered by the three parameters of response to 
TRAIL. Statistical analysis by Spearman correlation analysis. TRAIL-resistant tumors with IC50 to 
AZD6244 (○) or to BEZ235 (□) >0.2 M. All data represented by a color code indicating the ratio of the 
values for each tumor to the median value of each parameter in the whole panel. 
 
In fact, the association of TRAIL with small molecules inhibitors like AZD6244 or BEZ235 
should be able to increment the level of activation of the apoptotic cascade thanks to: 1) a 
concomitant targeting of both the extrinsic (mainly due to TRAIL activity) and the intrinsic 
apoptosis pathways; 2) the convergence of the stimuli on the mitochondrial dependent 
pathway of cell death; 3) possible effects of the inhibitors on the modulation of pro- and anti-
apoptotic molecules responsible for TRAIL resistance in melanoma cells. 
The association of TRAIL and target-specific agents should therefore lead to a higher degree 
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4.3 SYNERGISTIC ANTI- TUMOR EFFECTS through the CONCOMITANT 
TARGETING of ONCOGENIC and DEATH RECEPTOR PATHWAYS 
 
4.3.1 Chou-Talalay analysis of drug interaction  
 
Two melanoma cell lines susceptible to the inhibitors and TRAIL (Me1 and Me83) and two 
TRAIL resistant and poorly responsive to AZD6244 (Me13 and Me6), were then selected for 
the initial analysis of drug interaction. All possible two- and three-drug combinations were 
evaluated by the Chou and Talalay method using data from MTT assays (see ref.193 and 
section 3.4.2 for detailed description). 
This type of analysis generates a graphical output were fraction affected (FA) values are 
plotted versus combination index values (CI), giving a quantification of the synergistic 
interaction between the drugs used. Synergism is defined when CI values are lower than 




Figure 4.5 Drug interaction analysis by Chou-Talaly method. Fraction affected (Fa) vs Combination 
index (CI) plots in four melanoma cell lines (Me1, Me83, Me13, Me6) as assessed by a 48 h MTT 
assay followed by data analysis by Compusyn software. Cells were treated with combinations of 
AZD6244 (at 0.001, 0.005, 0.01, and 0.05 M), BEZ235 (at 0.005, 0.01, and 0.02 M) and TRAIL (at 5, 
10 and 25 ng/mL). Note that data points for CI values >150 are not shown.  
 
As shown in Figure 4.5, the outcome of drug interaction, both in terms of synergism/ 
antagonism and of fraction affected, was dependent not only on the specificity of the 
combination but also on dosing of each agent. However, two combinations were the best 
ones in achieving a strong synergism (CI<0.3) with high FA values in all four cell lines: the 
AZD6244-BEZ235-TRAIL and also the AZD6244-TRAIL combinations; moreover, the lowest 
CI values were observed when AZD6244 was used at 0.05 M (asterisks, Figure 4.5).  
Western blot analysis  of three different melanoma cell lines treated with AZD6244 at 0.05 
M or with BEZ235 at 0.02M confirmed that the relative targets of these drugs were 
effectively inhibited (Figure 4.6) 
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Figure 4.6 AZD6244 and BEZ235 effectively inhibit their targets. Me5, Me79 and Me71 melanoma 




4.3.2 Extended drug interaction analysis on a panel of melanoma cell 
lines 
 
Chou-Talalay drug interaction analysis was then extended to a panel of 21 melanoma cell 
lines selected for the known profile of susceptibility and resistance to both the inhibitors and 
TRAIL.  
To facilitate the understanding of the results, we created a color code to visualize results of 
combination indexes and fraction affected data; Figure 4.7 shows the correspondences 
between colors used and raw data values. Basically, red coloring indicates antagonism while 
greens shades indicates synergy; additive effects are instead represented in black. 
 
 
Figure 4.7 Correspondance between color code and raw values for both combination indexes 
and fraction affected data. 
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In Figure 4.8 data are reported using the color code described in Figure 4.7 and cell lines 
used are grouped in AZD6244- resistant (IC50 ≥0.2 M, n=7) and AZD6244- susceptible (IC50 
≤0.2 M, n=14).  
 
 
Figure 4.8 Chou and Talalay analysis of drug interaction in two groups of melanoma cell lines 
with different responsiveness to Selumetinib. Cell lines were treated with the association of 
AZD6244, BEZ235 and TRAIL (A), or AZD6244 and TRAIL (B), or  BEZ235 and TRAIL (C). The right 
hand side panel summarizes susceptibility profiles and main molecular features of all cell lines. 
Numbers at the bottom of each panel indicate median CI values and mean FA values for each 
combination. m: mutant; wt: wild type; +, -: expression/lack of expression of  PTEN by western blot. 
 
Results of the Chou-Talalay analysis on the panel of 21 melanoma cell lines confirmed that 
the AZD6244-BEZ235-TRAIL combinatorial treatment was the best in achieving a strong 
synergistic interaction between the drugs, with CI<0.3 and high levels of FA in all AZD6244-
resistant lines and in 13/14 AZD6244-susceptible lines (Figure 4.8A). Of note, the efficacy of 
three-drug combination was observed not only in cell lines resistant to the MEK inhibitor, but 
also in those with high IC50 values for BEZ235, or completely resistant to TRAIL, and was 
not associated to a particular mutational status of BRAF, NRAS, PTEN and/or p53 (as 
shown by table at the right hand of the figure).  
As expected, increasing doses of BEZ235 and of TRAIL were associated with further 
improvement in either CI (Figure 4.8A) or FA values (Figure 4.9). 
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Figure 4.9: Combinatorial treatments increment FA values. Box and whiskers plots of FA (Fraction 
affected) values by combinatorial treatment of AZD6244-resistant (n=7) melanoma cell lines treated 
with the association of AZD6244, BEZ235 and TRAIL 
 
Moreover, a detailed statistical analysis of raw FA data (Supplementary Table S2) indicated 
that a significant increment in FA values were achieved using TRAIL at the highest dose 
(25ng/ml) as well as if BEZ235 was added to AZD6244+TRAIL or TRAIL was added to the 
AZD6244+BEZ235 combinations. 
In the same panel of tumors, also the AZD6244-TRAIL combination achieved strong 
synergism values, again when AZD6244 was used at 0.05 M (Figure 4.8B), while in 
contrast in most instances the BEZ235-TRAIL combinatorial treatment showed marked 




Figure 4.10 Chou and Talalay analysis of drug interaction in two groups of melanoma cell lines 
with different responsiveness to Selumetinib. The same panel of cell lines (as in Figure 4.8) was 
treated with the association of AZD6244, BEZ235 and TRAIL (A), or AZD6244 and TRAIL (B), or  
BEZ235 and TRAIL (C). Numbers at the bottom of each panel indicate median CI values and mean FA 
values for each combination.  
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Based on the results summarized in Figure 4.10 (where  data are reported with color code 
used in Figure 4.7) at an AZD6244 dosage lower than 0.05 M (ranging from 0.001 M to 
0.01 M) CI values for both the AZD6244+TRAIL and AZD6244+BEZ235+TRAIL association 
indicated, in the vast majority of cell lines, antagonism and the BEZ+TRAIL combination was 
confirmed to exert antagonistic effects; also, at these conditions the percentage of cells 
affected, represented by the FA values, was significantly low (Figure 4.10).    
 
Taken together, these results indicated that association of MEK inhibitors, with or without 
PI3K/mTOR blockade, with TRAIL leads to synergistic anti-tumor effects, when AZD6244 is 
used at 0.05M, on most melanomas, both independently from their intrinsic resistance to 
inhibitors or to TRAIL and irrespective from the genetic background of the cell lines 
analyzed. 
 
4.5 COMBINATORIAL TREATMENTS RESCUE SUSCEPTIBILITY OF 
MELANOMA CELLS TO CASPASE-DEPENDENT APOPTOSIS 
 
4.5.1 Gene expression profiling of melanoma cells treated with 
inhibitors and TRAIL 
 
To gain insight into the main biological processes behind the positive association of MEK, 
PI3K/mTOR inhibitors and TRAIL, we decided to carry out a whole genome gene expression 
analysis.  
Since our goal was to identify the possible mediators of the activity our association, we 
selected for this type of experiment Me13 cells. This line was both resistant to TRAIL and 
poorly responsive to AZD6244 and BEZ235, but responded significantly (CI <0.01) to the 
combinatorial treatment. Whole genome gene expression studies were carried out on 
Illumina Bead Chip HumanHT-12_v4 Microarrays by the facility at our Institute. 
Class comparison analysis helped us to first identify the set of genes specifically modulated 
by the AZD6244-BEZ235-TRAIL association (examples visualized by Edwards-VENN 
diagrams, Figure 4.11A), and we subjected them to analysis by IPA (Ingenuity Pathway 
Analysis) software. 
We used the “downstream effects analysis”, a computational tool that, starting from 
observed changes in a dataset of gene expression, identifies  which biological functions are 
expected to be either decreased or increased. 
A significant up-regulation of the functions “cell death” and “apoptosis” and a down-
regulation of the functions “tumorigenesis”, “cell migration” and “proliferation” were identified 
(Figure 4.11B and Supplementary Table S3). 
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Figure 4.11 Combinatorial treatments induce modulation of the functions related to cell death. 
A) schematic representation of the subsets of genes modulated by different combinatorial treatments. 
B) Data from the gene expression profiling on melanoma cells treated with AZD6244+BEZ235+TRAIL 
were used to identify the specific set of genes affected by the three-drugs treatment (identified by light 
blue color) and these were then subjected to downstream effect analysis (by IPA). Only biological 
functions with significant z score statistic (>2, indicating increase of biological function, or <-2, 
indicating decrease of biological function). 
 
The same analysis was performed on genes modulated by the AZD6244-TRAIL association. 
Similarly, we used IPA to identify biological processes associated with the modulation of 
specific genes by combinatorial treatment (Figure 4.12A) and our results confirmed an 
increment of the functions “cell death” and “apoptosis” also for this two-drug combination 
(Figure 4.12B and Supplementary Table S4). 
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Figure 4.12 Treatments with AZD6244 and TRAIL modulate genes related to cell death. A) 
Edwards-VENN diagram representation of significantly modulated genes in Me13 cells treated with 
AZD6244 (red), TRAIL (blue) or their association (green). B) Downstream effect analysis on the 
subsets of genes identified by the green shape in panel a. Only biological functions with significant Z 
score statistic (>2, indicating increase of biological function, or <-2, indicating decrease of biological 
function) and significant overlap P value are shown.  
 
4.5.2 Apoptotic cell death and caspase activation 
To confirm results of gene expression profile and therefore the induction of melanoma cell 
death by the association, we performed annexin-V/PI flow cytometry assays to discriminate 
between apoptosis and necrosis.  
Figure 4.13 shows results of our experiments in terms of the sum of early (annexin-V+ PI-) 
and late (annexin-V+ PI+) apoptosis. Significantly higher levels of apoptotic cell death, 
compared to single agents, were observed in 5/8 tumors by AZD6244-TRAIL (p<0.01 by 
ANOVA followed by SNK test), and in 8/8 tumors by the three-drug combination (p<0.01 in 
7/8 tumors and p<0.05 in 1/8 tumors).  
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Figure 4.13 Combinatorial treatment induce melanoma apoptosis. Melanoma cells were treated 
with AZD6244 (0.05 M), BEZ235 (0.05 M), and TRAIL (25 ng/mL) and their combinations for 72 h, 









) apoptosis values. Statistical analysis by ANOVA followed by SNK test. ***: 
p<0.001, **: p<0.01; *: p<0.05 
 
Data reported in Figure 4.14 highlight that the increment in melanoma cell death achieved by 
combinatorial treatment is not dependent on the specific inhibitor used, but on the pathway 
being targeted, as the association of a different inhibitor of the MEK/ERK pathway 
(PD0325901) with TRAIL exerts similar effects in terms of apoptotic cell death if compared to 
single agents. Also in this case the addition of Rapamycin (an inhibitor of the 
PI3K/mTOR/AKT pathway) determines a further increment in melanoma cell death. 
 
 
Figure 4.14 Enhanced melanoma apoptosis by association of TRAIL with PD0325901 and 
Rapamycin. Me13 cells were treated with TRAIL (10 ng/mL), PD0325901 (5 nM), rapamycin (10 nM) 
or their combinations. Apoptosis was assessed at 72 h by flow cytometry (representative plots in A and 
mean values (± S.D.) for three independent experiments in B) p<0.001 for all comparisons, by ANOVA 
and SNK test. 
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Since the two pathways of apoptosis converge on the cleavage and induction of effector 
caspase-3/7, we then performed a caspase activation assays. 
Results, shown in Figure 4.15, indicated the AZD6244-BEZ235-TRAIL and AZD6244-TRAIL 
as the combinations to achieve a significantly higher activation of caspase 3/7, if compared 
to single agents (p<0.01) or to the association of the two target-inhibitors (p<0.01). 
 
 
Figure 4.15 Induction of caspase activity by combinatorial treatments. Caspase 3/7 activation in 
two melanoma cell treated with AZD6244 (0.05 M), BEZ235 (0.05 M), and TRAIL (25 ng/mL) and 
their combinations for 24 h. Mean values (± S.D.) for three independent experiments. Statistical 
analysis by ANOVA followed by SNK test. **: p<0.01 
 
To confirm the functional relevance of caspase activation for cell death induction by our 
association of drugs, we performed more annexin-V/Propiudium Iodide experiments with a 
pre-treatment of cells with a pan caspase inhibitor (z-VAD-fmk) and its relative control (z-FA-
fmk).  
As attended, the blockade of caspases activation completely abolished the increase in 
apoptosis induced by the addition of TRAIL to the AZD6244-BEZ235 combination, even in 
TRAIL-resistant (Me13) or in weakly susceptible (Me5) melanomas. No impact on cell death 
promoted by the two inhibitors together was seen (Figure 4.16).  
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Figure 4.16 Apoptosis induced by combinatorial treatments is caspase- dependent. Annexin-V/PI 
assays (A, single experiment; B, average of three experiments) in melanoma cells (Me 5, Me13) 
treated with AZD6244 (0.05 M), BEZ235 (0.05 M), and TRAIL (25 ng/mL) and their combinations for 
72h in the presence of the pancaspase inhibitor z-VAD-fmk or of the negative control peptide z-FA-fmk. 
Statistical analysis by ANOVA followed by SNK test. ***: p<0.001, **: p<0.01; *: p<0.05. 
 
As shown in Figure 4.17 we obtained similar results with the two-drug association (AZD6244 
+TRAIL), with apoptotic levels that, in the presence of caspase inhibition, go back to the 
ones obtained by Selumetinib treatment only. 
 
 
Figure 4.17 Apoptosis induced by the association of Selumetinib and TRAIL is caspase- 
dependent. Me5 and Me75 were treated with AZD6244 (0.05 mM) or TRAIL (25 ng/mL) or their 
combinations for 72 h, in the presence of the pancaspase inhibitor  z-VAD-fmk or of the negative 
control peptide z-FA-fmk, and apoptosis was assessed by Annexin-V/PI assay (A representative plots, 
B mean of three independent experiments). Results shown as sum of early and late apoptosis. Mean 
values (± S.D.) for three independent experiments. Statistical analysis by ANOVA followed by SNK 
test. ***: p<0.001, **: p<0.01.  
 
Taken together these results indicated that the concomitant targeting of MEK, with or without 
PI3K/mTOR inhibition, and of the TRAIL pathway has a synergistic anti-melanoma activity 
likely mediated by an enhancement of caspase-dependent apoptosis.  
Our hypothesis, therefore, was that the inhibitors used for our combinatorial treatment could 
operate at some level in TRAIL receptor cascade, modulating molecules responsible for 
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4.6 COMBINATORIAL TREATMENTS MODULATE SEVERAL PRO AND 
ANTI-APOPTOTIC MOLECULES  
 
To further dissect the mechanisms leading to the positive interaction demonstrated for our 
association of drugs, we decided to test whether combinatorial treatments had any impact on 
the expression of several pro- and anti-apoptotic molecules in both the extrinsic and intrinsic 
pathways of cell death. 
Western blot analysis of cells treated with the AZD6244-BEZ235-TRAIL combination 
revealed that this treatment significantly affected the expression of the caspase-8 inhibitor c-




Figure 4.18 Combinatorial treatments modulate several pro and anti-apoptotic molecules and 
induce caspase-8 activation and mitochondrial depolarization. A) Western blot analysis for c-FLIP 
expression in two melanoma cell lines (Me13 and Me41) treated with AZD6244 (A), BEZ235 (B), 
TRAIL (T) or the indicated combinations. B) flow-cytometry analysis for cleaved caspase-8 
(representative histograms and results in a panel of 9 cell lines). C) western blot analysis for 
expression of BIM, clusterin and BAX in Me13 cells treated as in (a). D)TMRE analysis for 
mitochondrial depolarization (representative histograms and results in a panel of 6 cell lines). Statistical 
analysis by ANOVA followed by SNK test; ***, p<0.001. 
 
This was demonstrated in two melanoma cell lines with different susceptibility profiles to the 
anti-tumor agents used: reduced levels of cFLIP were seen not only in Me41, partially 
responsive to TRAIL and susceptible to the inhibitors, but also in Me13 cells, less responsive 
to AZD6244 and resistant to TRAIL.  
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As expected, the same association induced also the most significant increment in caspase-8 
cleavage, as evidenced by flow cytometry experiments and confirmed in a panel of 9 other 
cell lines (Figure 4.18B).  
The efficacy of our treatment was documented also by analysis of several Bcl-2 family 
members: western blots showed an up-regulation of the pro-apoptotic isoforms BIMs and 
BAX a down-regulation of two isoforms (ps and s) of the Bax inhibitor Clusterin (Figure 




Figure 4.19 Combinatorial treatments down-regulate MCL-1. Western blot analysis of two 
melanoma cell lines (Me 13 and Me 41) treated or not with the indicated associations of AZD6244, 
BEZ235 (0.05M) and TRAIL (25 ng/ml) 
 
Moreover, as expected, the strongest increase in mitochondrial depolarization was exerted 
by the three-drug association if compared to single agents and to the AZD6244-BEZ235 
combination (Figure 4.18D), in agreement with the notion that Bcl-2 family members have a 
central role in the mitochondrial pathway of cell death. 
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Enhanced modulation of c-FLIP, and up-regulation of BIMs and BAX, but not of Clusterin, 
compared to single agents, as well as caspase-8 cleavage and mitochondrial depolarization 
were confirmed also for the AZD6244-TRAIL association (Figure 4.20). 
 
 
Figure 4.20 The association of Selumetinib and TRAIL modulates several proteins and induces 
caspase-8 activation and mitochondrial depolarization. A, B) Western blot analysis for c-FLIP, 
BIM, clusterin and BAX in melanoma cell lines treated with AZD6244 (A), TRAIL (T) or their 
combination (AT). C) Cleaved caspase-8 and D) TMRE assay for mitochondrial depolarization in a 
panel of 9 melanoma cell lines. Statistical analysis in C,D by ANOVA followed by SNK test; ** p<0.01; * 
p<0.05.  
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Since the Inhibitor of Apoptosis Proteins (IAP) is another group of molecules with important 
roles in programmed cell death, we also evaluated the expression of several members of 
this family.  
Treatment of the same two melanoma cell lines (Me13 and Me41) with AZD6244-BEZ235-
TRAIL induced a strong down-modulation of c-IAP1, c-IAP2, XIAP and 
Bruce/Apollon/BIRC6, but not of Survivin and Livin, if compared to the effects of single 
agents or to AZD6244-BEZ235 treatment (Figure 4.21). 
 
 
Figure 4.21 Combinatorial treatments modulate IAPs. Western blot modulation of IAP proteins by 
treatment of two melanoma cells lines (Me13 and Me41) with AZD6244 (A),  BEZ235 (B) TRAIL (T) 
and their combinations (AB, ABT); NT: untreated 
 
 
Similarly, the AZD6244-TRAIL association was able to down-modulate IAP-2, XIAP and, 
specially, Apollon/BIRC6 (Figure 4.22). 
 
 
Figure 4.22 The association of Selumetinib and TRAIL modulates the expression of several 
IAPs. Modulation of the indicated IAP proteins by treatment of melanoma cells (Me13) with AZD6244 
(A), or TRAIL (T) or AZD/TRAIL (AT) combination.  
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Since the giant IAP Apollon/BIRC6 was recently shown by our group to play a relevant role 
in suppressing melanoma response to several small molecules inhibitors and to TRAIL, and 
our experiments pointed at a crucial role of this molecule also in in this setting of treatments, 
we decided to evaluate it through silencing experiments by previously validated siRNA.
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As expected, Apollon silencing had no influence on untreated cells, but in cells treated with 
the MEK inhibitor, with or without BEZ235, and TRAIL, the absence of Apollon significantly 
reduced the % of live cells (Figure 4.23B).  
Correspondingly, Apollon silencing induced a marked increment in mitochondrial 





Figure 4.23 Apollon silencing  increments melanoma cell death and mitochondrial 
depolarization. A) Flow cytometry control of Apollon silencing. Effect of Apollon silencing on cell death 
(B) and on mitochondrial depolarization (C) in Me41 cells treated with the indicated agents and their 
combinations. Mean values (± S.D.) for three independent experiments; statistical analysis by ANOVA 
followed by SNK test; ***, p<0.001. **, p<0.01. 
 
Taken together, these results suggest that association of TRAIL with co-targeting of MEK 
and PI3K/mTOR, or with MEK blockade only, promotes effective melanoma cell death by 
affecting the expression levels of several molecules involved in the regulation of both the 
extrinsic and intrinsic apoptosis pathways, with Apollon modulation as a key effect promoted 
by combinatorial treatment. 
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4.7 IN VIVO ANTI-TUMOR ACTIVITY OF THE COMBINATORIAL 
TREATMENT THROUGH PROMOTION OF MELANOMA CELL DEATH 
AND INHIBITION OF ANGIOGENESIS 
  
4.7.1 Tumor growth inhibition in vivo  
 
Based on our positive in vitro results, we decided to verify if co-targeting of oncogenic and 
death receptor pathways could exert significant anti-tumor effects also in vivo.  
To this end, since both the three-drug (AZD/BEZ/TRAIL) and two-drug (AZD/TRAIL) 
associations shared synergistic anti-melanoma activity in vitro and similar mechanisms of 
apoptosis induction, we decided to investigate the effects of two-drug treatment with 
Selumetinib and TRAIL on melanoma xenografts.   
We started testing three melanoma cell lines selected to have different susceptibility to 
TRAIL, for their ability to grow subcutaneously in immune-compromised mice.  
All the three lines tested grew in vivo, with no sign of toxicity on mice results of increment in 
tumor volume over time are showed in Figure 4.24.  
 
 
Figure 4.24 Growth curves of 3 melanoma cell lines subcutaneously injected in female SCID 
mice.  
 
To evaluate the efficacy of our combination we then selected, among the cell lines tested for 
the ability to grow in vivo, the one that was TRAIL- resistant (Me13) and poorly responsive to 
AZD6244 and for which we already had good in vitro data on the response to drug 
association. 
Female SCID mice were injected with exponentially growing melanoma cells and, when 
tumors became palpable, were treated the MEK inhibitor or soluble TRAIL for two 
consecutive weeks. AZD6244 treatment of SCID mice bearing s.c. Me13 xenografts exerted 
a moderate tumor inhibition effect, while as expected TRAIL had no impact on tumor growth, 
confirming the resistance of this cell line also in vivo. 
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Figure 4.25 The association of Selumetinib and TRAIL significantly reduces tumor growth. 
Female SCID mice (n=7/group) bearing Me13 xenografts were treated between day 11 and day 25 
(dotted line) with AZD6244, TRAIL, or their combination. Statistical analysis by mixed models ANOVA; 
****: p<0.0001; ***: p<0.001; **: p<0.01. 
 
However, the AZD6244-TRAIL combination achieved a significant anti-tumor activity 
compared to single treatments, with a reduced tumor volume (Figure 4.25) and no 
associated sign of treatment-related toxicity as shown by histological analysis of main 




Figure 4.26 A) representative EE  stainings of tissue sections from liver, lung and spleen of control 
and treated mice. B) body weight analysis of individual mice (n=7/treatment group) during treatments. 
Results shown as % change in body weight compared to pre-treatment values of each mouse.    
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4.7.2 Enhanced tumor cell death in vivo  
 
To confirm an increment in promotion of melanoma cell death also in vivo, neoplastic 
nodules were removed at the end of treatment and analyzed for the presence of apoptotic 
cells by immunohistochemistry. 
Deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining revealed 
an enhanced positivity in the AZD6244-TRAIL association group, compared to single 
treatments. 
Moreover, higher levels of cleaved caspase 3 and a more pronunced down-modulation of 
pERK and Apollon were present in nodules from animals treated with combination of drugs if 
compared to vehicle treated, or single agent treated mice. (Figure 4.27). 
 
 
Figure 4.27 Immunohistochemistry analysis of tumor nodules from animals treated with 
combination of AZD6244 and TRAIL. Insets, higher magnification of a representative area of each 
panel. Original magnification, 20x.  
 
These results confirmed an effective inhibition of the ERK pathway, possibly more significant 
with combinatorial treatment than with single agents, and a synergistic promotion of 
melanoma cell death also in vivo by the two-drug regimen. 
 
4.7.3 Inhibition of angiogenesis by the concomitant targeting of MEK 
and TRAIL receptor  
 
Among the functions that downstream effect analysis evidenced as inhibited by the 
AZD6244-TRAIL association, “migration and proliferation of endothelial cells” was of 
particular interest for the possible indication of indirect effects of combinatorial treatment also 
on tumor microenvironment (Figure 4.12B).  
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We therefore subjected data to the “upstream regulator analysis”, a tool able to identify 
transcriptional regulators that can explain observed changes in gene expression of a 
dataset. As expected, the analysis on genes modulated by the association of AZD6244 and 
TRAIL, predicted a highly significant inhibition of several master regulator genes related to 
angiogenic processes, including TGF1, HGF, EGF, Myc, HIF1 and VEGF 
(Supplementary Table S5), in addition to MITF activation, which is a common consequence 
of ERK pathway inhibition. 
198
 
To confirm this hypothesis, we initially performed experiments on Me13 cells with protein 
array specific for angiogenesis-related molecules. As expected we found a strong down-
modulation of several molecules with key roles in the angiogenic process by the AZD6244-
TRAIL association (Figure 4.28).  
 
Figure 4.28 Protein array screening at 24 h after melanoma treatment. AZD6244, and TRAIL were 
used at 0.1 M, and 25 ng/mL respectively.   All molecules shown in the figure were significantly 
modulated, compared to control untreated cells, by the AZD6244+TRAIL combination (P at least <0.05, 
by ANOVA and SNK test). ***: p<0.001, **: p<0.01; *: P<0.05.  
 
A decreased expression of Myc and HIF1levels upon treatment of Me13 cells with 
AZD6244-TRAIL, or with AZD6244 only was confirmed by western blot analysis (Figure 
4.29A). 
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Moreover, to further confirm our results we decided to carry on ELISA experiments on 
supernatants from cells treated overnight with AZD6244-TRAIL and we found a significant 
suppression of VEGF and TGF1 secretion, in absence of melanoma cell death (Figure 
4.29B-E). Inhibition of VEGFsecretion by the association of MEK inhibitor and TRAIL was 





Figure 4.29 AZD6244 and TRAIL treatment modulates the production by melanoma cell lines of 
angiogenesis related molecules. A) Western blot analysis for Myc and HIF-1 in Me13 cells treated 
for 18 h in-vitro with AZD6244 (A), TRAIL (T) or their combination. B) Percentage of apoptosis in three 
different melanoma cell lines after treatment with Selumentinib, TRAIL or their combination for 18h. 
C,E) Secretion of  VEGF and TGF1 by Me13 treated in-vitro for 18 h with AZD6244, or TRAIL or 
their association. D) Inhibition of VEGF secretion in five melanoma cell lines by AZD6244+TRAIL 
treatment  for 18 h Statistical analysis by  ANOVA and SNK test; ***: p<0.001; **: p<0.01; *: p<0.05.  
 
Based on this preliminary in vitro evidence, we then analyzed the nodules from treated 
animals to confirm our hypothesis of effects of the AZD6244 and TRAIL combination also on 
tumor microenvironment. 
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Figure 4.30 The association of Selumetinib and TRAIL reduces tumor production of 
angiogenesis mediators. Me13 tumor nodules removed from control and treated mice were stained 
with  antibodies for HIF-1, VEGF and IL-8. Insets, higher magnification of a representative area of 
each panel. Original magnification, 20x. 
 
 
Immunohistochemistry staining for HIF-1, VEGF, and IL-8, a well-known target of HIF-1, 
showed that the concomitant treatment with MEK inhibitor and TRAIL was more effective 
than single agents alone in reducing the expression of these molecules also in vivo (Figure 
4.30). 
Moreover, analysis of very wide microscopy fields on HE stained sections (Figure 4.31A) 
showed a markedly reduced density of both large and small blood vessels; a result 




Figure 4.31 Combinatorial treatment reduces number of tumor vessels. A) Haematoxilin eosin 
staining of neoplastic nodules from mice treated with AZD6244, TRAIL and their combination. Arrows: 
large blood vessels. B) staining of Me13 nodules for murine CD31 endothelial cell marker. Two 
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representative fields (left and middle panel) and a higher magnification area (inset, right panel) are 
shown for each treatment group. 
 
Taken together, these data indicate that a combinatorial treatment approach that targets at 
least one relevant melanoma survival pathway (MEK-ERK) and the TRAIL signalling 
cascade has a positive anti-tumor activity in vivo not only with direct effects on tumor cells, 
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4.8 EFFECTS OF COMBINATORIAL TREATMENT ON ENDOTHELIAL 
CELLS 
 
Since one of the main effects of in vivo treatment with the combination of AZD6244 and 
TRAIL was a reduction in the expression of angiogenesis-related molecules (i.e. HIF-1, 
VEGF-, IL-8), associated with a marked decrease in density of blood vessels (CD31+ cells/ 
hematoxilin-eosin staining) in tumor nodules, we decided to test whether these two dugs 
affected vitality or phenotype of endothelial cells.  
As a model for endothelium we decided to use Human Umbilical Vein Endothelial Cells 
(HUVEC) and on these cells we initially evaluated TRAIL receptors expression and response 
to treatment with different doses of soluble TRAIL. 
As shown in Figure 4.32 although HUVECs expressed moderate levels of TRAIL-R1 and 
high levels of TRAIL-R2, treatment with their ligand had no effects on cell viability at any of 




Figure 4.32 TRAIL activity on HUVEC cells. A) TRAIL receptors expression on Huvec cells. B) 
Annexin-V and Propidium Iodide staining of Huvec cells treated or not with sTRAIL at 50-100ng/ml for 
72h. Representative dot plots and mean of three independent experiments. Statistical analysis by one-
way ANOVA followed by Newman-Kewls post test. 
 
We then decided to evaluate HUVEC response to AZD6244 as single agent and, despite the 
fact that already at the lowest dose used (0.01M) the phosphorilation of ERK was inhibited 
(Figure 4.33 A), no correspondent effects were seen on HUVEC cell death through annexin-
V/propidium Iodide stainings (Figure 4.33 B). 
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Figure 4.33 AZD6244 activity on HUVEC cells. A) Western blot analysis of Huvec cells for 
expression of total ERK and pERK after treatment with AZD6244 at 0.01-0.05-0.1M. B) Annexin-V 
and Propidium Iodide staining of Huvec cells treated or not with AZD6244 at the same doses for 72h. 
Mean of three independent experiments. Statistical analysis by one-way ANOVA followed by Newman-
Kewls post test. 
 
Interestingly, as shown in Figure 4.34, total cell death (by Annexin-V/Propidium Iodide) 
staining in HUVECs treated with the association of the MEK inhibitor and TRAIL was 




Figure 4.34 Treatment with Selumtinib and TRAIL induces Huvec cells apoptosis. Annexin-V and 
Propidium Iodide staining of Huvec cells treated or not with AZD6244 0.05 M, TRAIL 50 ng/ml or their 
association for 72h. Representative plots (A) and mean of three independent experiments (B). 
 
A significant increment in apoptosis was obtained by the combinatorial treatment if 
compared to untreated cells or to single treatment, suggesting a positive interaction between 
the two drugs also on endothelial cells. 
Nevertheless, since the increment in endothelial cell death achieved by treatment with the 
association of Selumetinib and TRAIL was, although significant, not sufficient in our opinion 
to justify the reduction of CD31
+
 cells seen in vivo experiments, we hypothesized that the 
anti-angiogenic effect of the MEK inhibitor-TRAIL association could be the result of a 
melanoma-induced modulation of the responsiveness of the tumor-associated vasculature to 
these agents.  To prove our hypothesis we set up co-culture experiments where endothelial 
cells are in direct contact with melanoma cells for up to 5/6 days.  
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Interestingly, if HUVEC were previously co-cultured with different melanoma cell lines, there 
was a tendency toward an increase in susceptibility to the association of Selumetinib and 
TRAIL in terms of apoptotic cell death (Figure 4.35). For co-culture experiments melanoma 
cells were identified using CD56, a molecule always expressed on the membrane of our 
melanoma cell lines; while endothelial cells were identified through the expression of CD31. 
 
 
Figure 4.35 Pre-conditioning with melanoma cells renders HUVEC more susceptible to 
AZD6244+TRAIL treatment. A) Gaiting strategy for the identification of endothelial cells  
(CD31+CD56-) and melanoma cells (CD56+CD31-). Annexin-V/PI stainings on Huvec cells after 5/6 
days of co-cultures with the indicated melanoma cell lines (Me1, Me13, Me43) and 48h hours of 
treatment with AZD6244 0.05uM and TRAIL 50ng/ml (B representative dot plots; C mean of three 
independent experiments). Statistical analysis by Two-way Anova analysis of variance followed by 
Bonferroni post test. * P< 0.05.  
 
These initial experiments confirmed our hypothesis that melanoma cells can alter the 
susceptibility of endothelial cells to TRAIL and  MEK inhibitor.  
 
It is well-known that tumor-associated vasculature is different from normal one 
199
 and, 
based on this notion, we hypothesized that the melanoma-HUVEC co-cultures could lead to 
a significant shift in the phenotypic profiles of the endothelial cells. 
As shown in Figure 4.36 A, and in agreement with the current literature, melanoma-HUVEC 
co-culture led to an upregulation of ICAM-1 (CD54) on endothelial cells, a finding that could 
be explained as “activation” of endothelial cells through the PKCα-p38-SP-1 pathway.
200
  
Interestingly, we also found evidence for modulation of molecules that are related to 
endothelial cell “differentiation” rather than to “activation”: in fact, two different melanoma cell 
Targeting melanoma death-resistance pathways 
Results  81 
lines induced a reduction in expression of vascular cadherin (CD144, cadherin 5). Notably, 
other molecules tested (i.e TRAIL-R2, CD202b) were not significantly affected by the co-
cultures (Figure 4.36 B) 
 
Figure 4.36: Co-cultures with melanoma cell lines induce modulation of ICAM-1 and CD144 on 
endothelial cells. Staining with the indicated antibodies on Huvec cells not treated (filled gray 
hystogram) or isolated after 5/6 days of co-cultures with Me1 (red hystograms) or Me43 (blu 
hystograms).  
 
Moreover, we noticed that two different melanoma cell lines (red and blu lines in Figure  
4.37) were different in inducing a down-modulation of the endothelial marker CD31 and the 
marker of EMT alpha smooth muscle actin (-SMA); furthermore, both melanoma cell lines 
induced an up-regulation of the receptor tyrosine kinase AXL. 
 
 
Figure 4.37 Staining with the indicated antibodies on Huvec cells not treated (filled gray hystogram) or 
isolated after 5/6 days of co-cultures with Me1 (red hystograms) or Me43 (blu hystograms).  
 
Based on these result we hypothesized that different melanoma cells (possibly depending on 
their own gene expression profile) may differentially regulate HUVEC differentiation stage 
and this in turn may impact on the endothelium responsiveness to drugs.  
To this end we have characterized 5 different melanoma cell lines for their gene expression 
profile and we have classified these tumors according to available melanoma classes 
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previously defined in the literature as “invasive” and “proliferative”. 
111
 Results indicated that 
while Me 1 belongs to the “invasive” family of tumors, Me 43 is instead in the “proliferative” 
group (data not shown). 
Starting from the observation that Me1 and Me43 not only belong to the two opposite family 
(proliferative and invasive) but also induce opposite effects on the expression of several 
molecules on endothelial cells, we further hypothesized that these melanoma can also differ 
for their expression of angiogenesis-related factors. 
We therefore selected a list of genes related to the angiogenic process and clustered our 5 
melanoma cell lines on the bases of their expression of these molecules. 
Interestingly, as shown in Figure 4.38, these two tumors are very different in terms of 
expression of this list of genes. 
 
 
Figure 4.38: Clustering of melanoma cell lines based on gene expression of angiogenesis 
related factors. 
 
Based on this evidence we decided to gain more insight into the changes to gene expression 
in endothelial cells if co-cultured with melanoma cell lines that belong to different classes 
(i.e. invasive vs proliferative). 
To this end we decided to perform long-term (>5 days) co-culture experiments between Me1 
or Me43 melanoma cells and HUVEC, aimed at analyze the gene expression profile of pre-
conditioned endothelial cells. 
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We have therefore developed an assay that allows the isolation of pure endothelial cells 
after co-culture with melanoma cell lines using negative magnetic separation with anti 




Figure 4.39: Magnetic beads allow separation of pure endothelial cells from co-cultures with 
melanoma cell lines. Melanoma cells and Huvec cells co-cultured for 6 days. Endothelial cells are 
purified through magnetic separation with anti-melanoma beads (anti-MCSP beads Miltenyi Biotec) 
and stained for CD56 and CD31. Purity over 97%.  
 
 
Gene expression profiling of HUVEC cells previously co-cultured with melanoma cell lines 
belonging to the two different classes are ongoing and results will be analyzed in the next 
months.  
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Melanoma is an aggressive disease with an always increasing incidence and hardly 
curable when in advanced stage. Despite recent and impressive improvements achieved in 
melanoma treatment due to the development of target specific drugs (i.e. Vemurafenib, 
Dabrafenib and Trametinib) as well as of monoclonal antibodies targeting immune 
checkpoints (i.e. Ipilimumab, Nivolumab), there is still a fraction of patients that do not 
respond to this type of approaches or that relapse quickly after treatments, for which other 
alternatives are urgently required. 
 
Different strategies are being investigated to face the need of new therapeutic options, one 
of which is the possibility to overcome melanoma resistance to different anti-tumor agents 
and to rescue tumor susceptibility to cell death through combinatorial treatments.  
Recent pre-clinical studies have investigated several options, such as the co-targeting of 




 the association of Vemurafenib with 
inhibitors of autophagy 
203
, ER-stress inducers 
204
, or combination of other anti-tumor agents 




Based on the knowledge that target specific inhibitors are being widely tested in clinical trials 
for melanoma treatment, and building upon the hypothesis that a good therapeutic strategy 
should not only target tumor cells, but also relevant pro-tumoral mechanisms in melanoma 
microenvironment, such as angiogenesis, we decided to test, in melanoma cell lines and in 
melanoma xenografts, the effects of the co-targeting of MAPK, PI3K and death receptors 
cascades.  
In this work we have collected evidence demonstrating that the association of TRAIL and a 
MEK inhibitor such as AZD6244, with or without the addition of a PI3K pathway inhibitor, 
exerts synergistic anti- melanoma effects both in vitro and in vivo. This was shown to be due 
to a dual activity affecting not only tumor cells, but also tumor microenvironment. 
The first, direct effect of the association between TRAIL and the signalling pathway inhibitors 
used, was the possibility to overcome melanoma intrinsic resistance to each agent and to 
achieve significantly low values of Combination Indexes, even in cell lines completely 
resistant to one of both of the drugs.  
Importantly, synergism was observed not only in BRAF mutant cell lines, but also in NRAS 
mutant or wild-type ones; indicating that this combinatorial approach could potentially be 
widely used and not limited to a sub-group of patients. Moreover, a synergistic interaction 
between the drugs was seen independently from the mutational status of p53 or PTEN, two 
genes known to be involved in melanoma resistance to target therapy 
121,208
 
In contrast, the association between TRAIL and BEZ235 only, without the addition of the 
MEK inhibitor, was characterized by a marked antagonism, suggesting that the effects seen 
for the AZD6244-TRAIL combination are peculiar and cannot be achieved by the inhibition of 
a different well known oncogenic signalling pathway. 
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Gene expression experiments, analysis of caspases activation and cell death assays in the 
presence of the pan-caspase inhibitor z-VAD-fmk, indicated that both the two- drug 
(AZD6244+TRAIL) and the three-drug associations achieved anti-tumor effects through a 
direct induction of caspase-dependent melanoma apoptosis. This evidence supported us in 
the hypothesis that combinatorial treatments could counteract apoptosis- resistance 
mechanisms behind melanoma intrinsic resistance to monotherapy with TRAIL or target 
specific inhibitors. 
Analysis of the expression of several components of the intrinsic and extrinsic pathway of 
apoptosis confirmed our idea. Several studies report that cFLIP, the main caspase-8 
inhibitor, is overexpressed in human melanoma lesions and is one of the main mechanisms 
of melanoma resistance to TRAIL-induced cell death: indeed, as shown by Ivanov et al. 
209
, 
cFLIP down-regulation is sufficient to revert resistance to TRAIL of TRAL-R2+ melanoma 
cells. In our experiments we found that the association of AZD6244 and TRAIL, with or 
without BEZ235, induced a strong down-regulation in the expression of cFLIP long and short 
isoforms, associated with caspase-8 activation. 
Furthermore, we hypothesized that the rescue of caspase-8 activation through reduction in 
cFLIP-L/s levels could not be sufficient to explain the overall pro-apoptotic effect of the 
combinatorial treatments but that additional effects on molecules belonging to mitochondrial 
pathway of apoptosis were likely to be present. 
Recent works by Eberle et al indicate that Bax direct or indirect targeting could represent an 
applicable strategy to overcome resistance of melanoma cells to TRAIL-induced 
apoptosis
109,206
 ; moreover, in melanoma, inhibition of Bim by siRNA was found to attenuate 
conformational changes of Bax 
210
 and clusterin is known to specifically interact with 
conformation-altered Bax in response to chemotherapeutic drugs 
211
. Based on this 
knowledge, we decided to evaluate modulation of these molecules by our treatments; as 
expected, we found a strong up-regulation of the pro-apoptotic BIMs and BAX isoforms and 
a parallel reduction in clusterin and Mcl-1 by drugs association. Interestingly, BIM is not only 
a key mediator of TRAIL-induced cell death, but in diffuse large B cell lymphoma BIM was 
demonstrated to mediate the apoptotic response to AZD6244 and to BEZ235 in KRAS-




 These results, therefore, suggest that the association 
of AZD6244+/- BEZ235 and TRAIL targets a BIM-BAX axis, inducing mitochondrial 
depolarization and contributing to melanoma cell death. 
The over-expression of several IAPs, through the inhibition of both the initiator and the 
effector caspases, is well known to contribute to apoptosis resistance in different tumor 




 Our lab previously reported the central role of the giant 
IAP Apollon/BIRC6 in modulating melanoma response to several signalling inhibitors 
197
 and 
interestingly here we found that, among all IAPs, the one that was most significantly 
modulated by the association of AZD6244+/- BEZ235 and TRAIL was BIRC6/Apollon, whose 
central role was confirmed by silencing experiments. 
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Mechanistically, therefore, we could conclude that the association of target specific inhibitors 
and TRAIL had synergistic effects in terms of incremented melanoma apotosis likely 
mediated by the reduction of cFLIP expression, BIM and BAX activation, and the down-
regulation of Apollon expression. 
These results were confirmed also in an in vivo model, were tumor growth of melanoma 
xenografts was significantly reduced by the combined treatment along with an increment in 
TUNEL and cleaved caspase-3 staining and a reduced expression of Apollon in tumor 
nodules. 
 
Previous reports demonstrated that TRAIL treatment in vivo is able to disrupt tumor 
vasculature through induction of TRAIL receptor up-regulation on endothelial cells 
214
; 
moreover, TRAIL can negatively regulate VEGF-induced angiogenesis 
215
 and TRAIL and 
concomitant inhibition of MEK and VEGFR has been reported to reduce tumor angiogenesis 
in lung cancer models. 
191
 Based on these evidences we decided to evaluate effects of 
combining TRAIL and AZD6244 on tumor microenvironment.  
Initial in vitro experiments confirmed inhibitory effects of AZD6244+TRAIL on master 
regulators of angiogenesis, such as TGF, HIF-1 and Myc, as well as on production of pro-
angiogenic molecules such as VEGF in absence of melanoma cell death. 
The evaluation of CD31+ cells in nodules from melanoma xenografts after mice treatment 
with the MEK inhibitor and TRAIL confirmed also in vivo the effects of reduced angiogenesis, 
that was paralleled by a reduced staining for HIF-1, VEGF and IL-8. 
These results confirmed the presence of an indirect effect of the association studied, 
mediated by the activity of the two drugs on tumor microenvironment through a reduced 
promotion of angiogenesis. 
 
The next goal was then to identify mechanisms behind the evidence of a reduced number of 
vessels in nodules after combinatorial treatment. 
Our first hypothesis was a direct effect of AZD6244 and TRAIL on endothelial cells; but no 
induction of cell death was evidenced on an endothelial cell line after treatment with single 
agents, despite the expression of TRAIL receptors on HUVECs and the inhibition on 
MEK/ERK signalling pathway by AZD6244 at the doses used.  
The association of MEK inhibitor and the pro-apoptotic ligand was able to slightly increase 
the extent of endothelial apoptosis, but although significant, in our opinion it was not 
sufficient to justify the reduction of CD31+ cells seen in vivo experiments. Based on these 
results we hypothesized that the anti-angiogenic effect of the MEK inhibitor-TRAIL 
association could be the result of a melanoma-induced modulation of the responsiveness of 
the tumor-associated vasculature to these agents. 
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Initial experiments confirmed our hypothesis evidencing a tendency toward an increase in 
endothelial cell death, upon AZD6244+TRAIL combinatorial treatment, after co-culture with 
melanoma cell lines. 
Subsequent experiments, aimed at clarify mechanisms behind the effects seen, 
demonstrated a modulation of several molecules in endothelial cells after the co-cultures 
with different melanoma cell lines. 
Notably, data demonstrated not only an incremented “activation” of endothelium by direct 
interaction with tumor, seen through an up-regulation of ICAM-1 and expected by previous 
reports, but also a modulation of molecules known to play significant roles in endothelial cell 
differentiation (such as an increment in cadherin-5 and a reduced expression of CD31). This 
evidence could suggests us that melanoma cells induce a “re-programming” of endothelial 
cells.  
Moreover, we noticed that two melanoma cell lines seem to differentially induce modulation 
of the expression of SMA as well of CD31. This observation suggested us that different 
melanoma cell lines could differentially influence endothelial cells.  
To test this hypothesis we selected 5 melanoma cell lines and clustered them on the basis of 
their expression of a set of genes known to play key roles in the angiogenic process. 
In 2011, Hoek at al showed that melanoma cells with a “proliferative” phenotype were 
responsive to MAPK inhibition and a recent paper published by Garraway et al. 
demonstrated that melanoma cells with different sensitivity to MAPK pathway inhibitors, 
display distinct transcriptional profiles and are characterized by differential expression of 
MITF, NF-κB and the receptor tyrosine kinase AXL (“invasive” vs “proliferative”). 
Interestingly, the two melanoma cell lines found to be opposite for the expression of several 
group of angiogenesis-related factors, belong to two different classes if we divide the same 
melanoma cell lines on the bases of the classification proposed by Garraway.  
Starting from this notion, and in order to clarify if different melanoma cell lines (invasive vs 
proliferative) could differentially influence endothelial cell proliferation/maturation/phenotype, 
we decided to set-up gene-expression experiments on endothelial cells previously co-
cultured with melanoma cell lines and purified through magnetic separation. Results will be 
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Aim of the presented project was to obtain pre-clinical evidence for a possible strategy to 
overcome melanoma resistance to apoptosis could be represented by the concomitant 
targeting of oncogenic signalling pathways  and the TRAIL receptors, pro-apoptotic pathway. 
 
The chosen drugs (Selumetinib, BEZ235 and TRAIL) were tested in vitro in a large panel of 
short-term melanoma cell lines for  synergistic interactions and the best combination 
identified was verified for anti-tumoral effects also in vivo. 
 
Results of this work suggest that concomitant targeting of melanoma oncogenic signalling 
pathways and the TRAIL receptor cascade: 
 
1) is able to overcome in vitro tumor resistance to either agent with irrespective from 
the main genetic alteration present in melanoma cells; 
2) has synergistic effects in terms of induction of melanoma cell death by promoting a 
caspase-dependent apoptosis through the modulation of pro and anti-apoptotic 
molecules such as BIM, BAX, c-FLIP and Clusterin, along with a reduction in several 
members of the IAP family; 
3) has a key mediator of the effects Apollon/BIRC6; indeed its silencing is sufficient to 
sensitize melanoma cells to inhibitors or TRAIL –induced cell death 
4) reduces the production of key mediators of tumor-promoted angiogenesis (i.e. 
VEGF, TGF, IL-8) 
 
In addition the association of Selumetinib and TRAIL in vivo: 
 
5) reduces tumor growth of melanoma xenografts through induction of cancer cell 
death (increment in TUNEL positive cells), likely through the same mechanisms 
demonstrated for the in vitro synergy (i.e. Apollon/BIRC modulation) 
6) reduces the presence of main mediators of angiogenesis in tumor sections from 
xenografted mice 
7) reduces number of CD31+ cells in tumor nodules 
8) changes the structure and integrity of tumor vessels (Hematoxylin-eosine staining) 
 
Moreover, initial/preliminary results conducted on a model of endothelial cells suggest that 
there is a possible modulation of endothelial differentiation status and responsiveness to 
combinatorial therapy fuelled by direct interaction with melanoma cells and evidenced by: 
 
9) upregulation of ICAM-1/CD54 on endothelial cells after co-culture  with  melanoma 
cell lines, indicating an endothelial “activation”; 
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10) a modulation of the “differentiation” status of endothelial cells, indicated by reduced 
levels of alpha-SMA, a reduction in the expression of vascular cadherin CD144 and 
a downmodulation of the endothelial marker CD31 after co-cultures between 
melanoma and HUVEC cells. 
 
All these data represent a pre-clinical rationale for a pro-apoptotic and anti-angiogenic 
strategy for melanoma treatment based on the association between inhibitors of main 





On the bases of the results just summarized, we are currently performing experiments aimed 
at: 
1) evaluating changes in the gene expression profile (Illumina array) of HUVEC cells 
after co-culture with melanoma cell lines; 
 
2) verifying if melanomas with different AXL/ MITF status could be different in affective 
responsiveness of endothelial cells after co-culture experiments; 
 
 
3) indentifying mechanisms behind the reduced production by melanoma cells of 
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Table S1 Molecular and biological features of melanoma cell lines used in this  study 
 
  
Molecular features of the cell linesb 
 
Susceptibility to TRAILc 
(MTT assay, 100ng/mL, 48h) 
Susceptibility to MEK 
and PI3K/mTOR 
inhibitorsd                
(MTT assay, 48 h) 
 
Tumor code 
used in this 
study 
 

















(% TMRE‐ cells) 
 
Caspase‐8 activation 














Me1 ln met. BRAFV600E wt/+ wt 94.1 49.0 28.0 0.050 0.080 Me14464 27, 42, 48 
Me2 ln met. BRAFV600E wt/+ wt 76.5 58.0 32.0 0.120 0.225 Me4023 27, 48 
Me5 s.c. met. BRAFV600E ex.5 del403‐409/‐ wt 26.0 12.2 16.0 0.015 0.070 ‐ This manuscript 
Me6 s.c. met. BRAFV600E wt/+ wt 28.0 43.6 28.3 0.350 0.088 Me6824 42 
Me13 ln met. BRAFV600E wt/+ wt 6.2 4.7 2.6 0.308 0.109 Me15392 27, 42, 48 
Me15 ln met. BRAFV600E wt/+ wt 96.4 14.2 33.0 0.015 0.045 Me23682 27 
Me17 ln met. BRAFV600E wt/+ C135W
Ho
 4.0 1.7 4.5 0.029 0.092 ‐ This manuscript 
Me20 ln met. NRASQ61R wt/+ wt 9.3 26.7 19.0 0.010 2.520 Me18816 42 
Me25 local recurrence BRAFV600E wt/+ Y236H 10.4 5.5 0.0 0.328 0.110 Me1402r 48 
Me27 ln met. BRAFV600E wt/‐ wt 17.0 19.6 16.3 0.186 0.178 Me13294 27 
Me30 ln met. BRAFV600E wt/+ wt 44.6 1.6 4.5 0.058 0.586 Me18656 27, 42, 48 
Me32 VGP primary me. NRASG12S wt/+ wt 87.4 23.9 0.1 0.410 0.030 Me9923p 48 
Me33 ln met. BRAFV600E wt/+ wt 0.0 0.0 0.5 0.023 0.283 ‐ This manuscript 
Me34 ln met. NRASQ61R wt/+ Y126H
Ho
 71.5 15.3 14.4 0.560 0.030 ‐ This manuscript 
Me36 ln met. wt/wt wt/+ wt 30.0 0.5 5.7 0.780 1.630 Me879 48 
Me40 ln met. BRAFV600E wt/‐ wt 1.5 0.1 17.3 0.280 0.100 ‐ This manuscript 
Me41 ln met. BRAFV600E wt/+ wt 35.0 20.5 6.5 0.020 0.048 Me32562 42 
Me43 ln met. BRAFV600E wt/+ wt 42.2 2.2 13.1 0.029 0.168 Me18732 27, 42, 48 
Me44 ln met. BRAFV600E wt/+ wt 4.7 0.6 7.0 0.050 0.220 Me16938 42 
Me46 s.c. met. BRAFV600E wt/+ wt 7.9 1.5 1.0 0.020 0.030 ‐ This manuscript 
Me49 ln met. BRAFV600E P246S/+ S127F
Ho
 19.8 0.0 1.1 0.049 0.089 Me2211 27, 42, 48 
Me50 ln met. BRAFV600E P246S
He/+ S127FHo 53.4 12.6 9.5 0.060 0.160 ‐ This manuscript 
Me53 s.c. met. BRAFV600E wt/+ wt 44.0 17.6 12.0 0.288 0.012 Me32669 27, 42 
Me55 ln met. wt/wt wt/+ wt 63.0 9.7 20.0 0.720 1.140 Me3700 42 
Me56 ln met. BRAFV600E P38S/‐ S127F 8.1 0.0 3.6 0.012 3.679 Me4686 48 
Me57 VGP primary me. wt/wt wt/+ R213R 2.4 3.2 0.6 0.020 0.020 Me1007 48 
Me58 ln met. BRAFV600E wt/+ wt 11.0 22.9 12.0 0.387 5.429 Me2559 42 
Me59 ln met. NRASQ61R wt/+ wt 29.4 21.7 0.0 0.030 0.590 Me4473 42, 48 
Me63 ln met. BRAFV600E Y223STOP
He / ‐ wt 25.8 3.1 0.8 0.085 4.796 ‐ This manuscript 
Me64 ln met. wt/wt nd/+ wt 3.3 0.8 1.7 0.050 0.020 Me13923 48 
Me67 soft tissue met. NRASQ61R wt/+ R213R
He
 92.5 25.5 25.0 9.770 0.380 Me3044 42 
Me69 ln met. BRAFV600E wt/+ Y234C 46.7 15.5 10.5 0.214 12.882 Me17697 48 
Me71 ln met. BRAFV600E wt/+ wt 3.5 17.7 25.0 0.010 0.047 Me21158 27, 42 
Me73 ln met. BRAFV600E delex 3‐5‐6/‐ P128S
He
 18.0 5.3 0.0 0.019 0.062 Me1274 42 
Me75 VGP primary me. BRAFV600E wt/+ wt 0.0 1.5 5.8 0.047 0.222 Me10258 42 
Me76 ln met. BRAFV600E wt/+ E258K 21.4 0.0 0.8 0.016 0.067 Me14362 27, 42, 48 
Me78 ln met. BRAFV600E wt/+ wt 10.5 0.0 1.3 0.069 6.098 ‐ This manuscript 
Me79 ln met. BRAFV600E wt/+ wt 17.0 4.3 1.9 1.224 96.746 Me2934 27, 42, 48 
Me83 ln met. wt/wt Q171Q / + wt 65.7 13.8 11.0 0.120 0.100 Me2352 27, 42 
Me85 VGP primary me. BRAFV600E wt/+ wt 49.0 38.9 6.3 0.014 0.525 ‐ This manuscript 
Me86 soft tissue met. NRASQ61R wt/+ wt 48.1 23.0 22.0 0.020 0.200 Me15094 27 
Me88 ln met. wt/wt wt/+ wt 71.1 12.0 0.0 0.020 0.160 Me19410 42 
Me92 VGP primary me. BRAFL596S wt/+ G187S 0.7 3.6 0.0 0.069 0.107 Me20842 27, 42, 48 
Me93 ln met. BRAFL596S wt/+ wt 8.5 5.7 0.9 0.036 0.076 Me20842M1 48 
Me94 s.c. met. BRAFL596S wt/+ G187S 51.2 12.2 2.7 0.018 0.048 Me20842M2 48 
Me96 ln met. BRAFV600E wt/+ wt 17.2 0.0 0.6 0.030 0.280 Me9874 42 
Me98 ln met. BRAFV600E nd/+ wt 0.0 0.5 0.8 0.042 0.048 Me29318 42 
Me99 VGP primary me. BRAFV600E P89S, delex 6‐8 /‐ wt 13.5 2.0 0.7 8.697 0.212 Me26635 42 
Me100 VGP primary me. NRASQ61R wt/+ null 52.1 0.0 2.2 0.120 0.560 Me4405 27, 42, 48  
a Melanoma cell lines were isolated from: vertical growth phase primary melanomas (VGP primary me.), lymph node metastases (ln met.), subcutaneous metastases 
(s.c. met.), soft tissues metastases or local recurrences. 
bMethods for identification of BRAF, NRAS, PTEN and p53 mutations are described in Grazia G. et al. Cell Death and Disease 2014. PTEN data expressed as gene 
sequence data / protein expression by 
western blot. He:heterozygous; Ho: homozygous. 
cSusceptibility to TRAIL was assessed by a 48 h MTT assay. Mitochondrial depolarization (TMRE assay) and caspase‐8 cleavage in response to TRAIL were assessed at 24 
h by flow cytometry. 
d Susceptibility to AZD6244 and BEZ235, shown as IC values, was assessed by a 48 h MTT assay. IC50 values were obtained trough non linear regression analysis of dose 
response curves. See Fig. 4.3 for representative examples of dose‐response plots. 
 Table S2. Statistical analysis of fraction affected (FA) data.   
 
  Comparison 1:  High vs. low TRAIL doses in the AZD6244+BEZ235+TRAIL combination: significant FA increase at higher TRAIL doses   
 
 FA values in melanoma cells 







BEZ235 → 0.005 µM 0.005 µM 
































: AZD6244 (0.05 µM) 
BEZ235 (0.005 µM) 




AZD6244 (0.05 µM) 
BEZ235 (0.005 µM) 












BEZ235 → 0.01 µM 0.01 µM 
































: AZD6244 (0.05 µM) 
BEZ235 (0.01 µM) 




AZD6244 (0.05 µM) 
BEZ235 (0.01 µM) 




 FA values in melanoma cells 







BEZ235 → 0.02 µM 0.02 µM 
































: AZD6244 (0.05 µM) 
BEZ235 (0.02 µM) 




AZD6244 (0.05 µM) 
BEZ235 (0.02 µM) 





  Comparison 2: AZD6244+TRAIL vs. AZD6244+BEZ235+TRAIL: significant FA increase by adding BEZ235   
 
 FA values in melanoma cells treated with the association  of: 
AZD6244 → 0.05 µM 0.05 µM 0.05 µM  AZD6244 → 0.05 µM 0.05 µM 0.05 µM  AZD6244 → 0.05 µM 0.05 µM 0.05 µM 
BEZ235 → 0.005 µM 0.01 µM 0.02 µM BEZ235 → 0.005 µM 0.01 µM 0.02 µM BEZ235 → 0.005 µM 0.01 µM 0.02 µM 
































: AZD6244 (0.05 µM) 
TRAIL (5 ng/mL) 
 * ** ***  
AZD6244 (0.05 µM) 
TRAIL (10 ng/mL) 
 
AZD6244 (0.05 µM) 
TRAIL (25 ng/mL) 
 
 
  Comparison 3: AZD6244+BEZ235 vs AZD6244+BEZ235+TRAIL: Significant FA increase by adding high dose TRAIL   
 
 FA values in melanoma cells treated with the association  of: 
AZD6244 → 0.05 µM 0.05 µM 0.05 µM  AZD6244 → 0.05 µM 0.05 µM 0.05 µM  AZD6244 → 0.05 µM 0.05 µM 0.05 µM 
BEZ235 → 0.005 µM 0.005 µM 0.005 µM BEZ235 → 0.01 µM 0.01 µM 0.01 µM BEZ235 → 0.02 µM 0.02 µM 0.02 µM 
































: AZD6244 (0.05 µM) 
BEZ235 (0.005 µM) 
 ns ns ***  
AZD6244 (0.05 µM) 
BEZ235 (0.01 µM) 
 
AZD6244 (0.05 µM) 
BEZ235 (0.02 µM) 
 
 
The analysis, carried out by ANOVA followed by SNK test, is based on FA data generated by Compusyn software on a 
dataset of the 21 melanoma cell lines and treated with the indicated combinations of target‐specific inhibitors and TRAIL. 
 *: p<0.05; **: p<0.01; ***: p<0.001   
ns ** *** 
 ns ** *** 
 
ns ns *** 
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